Support structures and methods of using the same

Information

  • Patent Grant
  • 11045200
  • Patent Number
    11,045,200
  • Date Filed
    Tuesday, February 19, 2019
    5 years ago
  • Date Issued
    Tuesday, June 29, 2021
    2 years ago
Abstract
An apparatus for forming an anastomosis between adjacent intestinal sections of tissue includes an anastomosis device having an anvil and a tubular body portion, wherein the anvil is selectively attachable to the tubular body portion by a shaft; and a support structure for deposition between the intestinal sections of tissue. The support structure includes a body defining an aperture therein for receiving the shaft. The body has an outer terminal edge. The support structure includes at least one layer of expandable material disposed at the outer terminal edge of the body.
Description
BACKGROUND
Technical Field

The present disclosure relates to support structures and, more particularly, to annular support structures, gaskets and the like for use in conjunction with stapling devices, for reducing occurrences of leaking, bleeding and/or stricture.


Background of Related Art

Staples have traditionally been used to replace suturing when joining or anastomosing various body structures, such as, for example, the bowel or bronchus. The surgical stapling devices employed to apply these staples are generally designed to simultaneously cut and seal an extended segment of tissue in a patient, thus vastly reducing the time and risks of such procedures.


Linear or annular surgical stapling devices are employed by surgeons to sequentially or simultaneously apply one or more linear rows of surgical fasteners, e.g., staples or two-part fasteners, to body tissue for the purpose of joining segments of body tissue together and/or for the creation of anastomoses. Linear surgical stapling devices generally include a pair of jaws or finger-like structures between which body tissue to be joined is placed. When the surgical stapling device is actuated and/or “fired”, firing bars move longitudinally and contact staple drive members in one of the jaws, and surgical staples are pushed through the body tissue and into/against an anvil in the opposite jaw thereby crimping the staples closed. A knife blade may be provided to cut between the rows/lines of staples. Examples of such surgical stapling devices are described in U.S. Pat. Nos. 4,354,628, 5,014,899 and 5,040,715, the entirety of each of which is incorporated herein by reference.


Annular surgical stapling devices generally include an annular staple cartridge assembly including a plurality of annular rows of staples, typically two, an anvil assembly operatively associated with the annular cartridge assembly, and an annular blade disposed internal of the rows of staples. Examples of such annular surgical stapling devices are described in U.S. Pat. Nos. 5,799,857 and 5,915,616 to Robertson et al., the entirety of each of which is incorporated herein by reference.


For most procedures, the use of bare staples, with the staples in direct contact with the patient's tissue, is generally acceptable. The integrity of the tissue will normally serve to prevent the staples from tearing out of the tissue and compromising the sealing before healing has occurred. However, in some surgical operations, surgical supports, e.g., meshes, are employed by surgeons to bridge, repair and/or reinforce tissue defects with a patient, especially those occurring in the abdominal wall, chest wall, diaphragm and other musculo-aponeurotic areas of the body. Examples of surgical supports are disclosed in U.S. Pat. Nos. 3,054,406, 3,124,136, 4,347,847, 4,655,221, 4,838,884 and 5,002,551, the entirety of each of which is incorporated herein by reference.


When the staples are applied in surgical procedures utilizing surgical supports (i.e., reinforcing material), the legs of the staple typically pass from the cartridge jaw through a layer of the surgical support, and through the patient's tissue before encountering the anvil jaw. In an alternative procedure, the legs of the staple typically pass from the cartridge jaw through a first layer of the surgical support, then through the patient's tissue, and finally through a second layer of the surgical support before encountering the anvil jaw. With the staples in place, the stapled tissue is clamped between the layers of the surgical support.


While the surgical supports described above are used in conjunction with linear surgical stapling devices, the need exists for annular support structure for use in conjunction with annular or circular surgical stapling devices, for example, an end-to-end anastomosis stapler such as a Model “EEA™” instrument available from United States Surgical, a Division of Tyco Health-Care Group, LP, Norwalk, Conn. and disclosed in U.S. Pat. No. 5,392,979 to Green et al. In general, an end-to-end anastomosis stapler typically places an array of staples into the approximated sections of a patient's bowels or other tubular organs. The resulting anastomosis contains an inverted section of bowel which contains numerous “B” shaped staples to maintain a secure connection between the approximated sections of bowel.


In addition to the use of surgical staples, biological tissue adhesives have been developed for tissue repair and the creation of anastomoses. Generally, biological adhesives bond separated tissues together to aid in the healing process and to enhance the tissue strength. Such adhesives may be used instead of suturing and stapling, for example, in surgical procedures, for the repair of tissue or the creation of anastomoses.


In addition to the use of biological adhesives, following the formation of the anastomosis, a separate instrument or device is used to apply biological sealants to the outer surface of the anastomosis. Typically, in a separate step, the biological sealants are applied to the outer surface of the anastomosis by spraying on, brushing on, swabbing on, any combinations thereof, or any other method contemplated by those skilled in the art. The biological sealants act to reduce and/or stop the incidents of leakage from the anastomosis.


One possible side effect of any end-to-end bowel anastomosis is its tendency to stenos over time, which stenosis can decrease the diameter of the lumen over time. Accordingly, the need exists for a surgical support structure which operates in conjunction with any end-to-end anastomosis device and assists in maintaining the lumen of the anastomosed bowel or other tubular organ open over time.


The application of suitable biocompatible adhesive offers many advantages to the patient and the surgeon alike, such as, for example, the possible reduction in the number of staples used, immediate sealing of the tissue being treated, a strengthening of the anastomosis, and a reduction in the occurrence of bleeding from the blood vessels, leakage through the tissue joint, and stricture. Moreover, use of biocompatible adhesives tends to minimize foreign body reaction and scarring.


Accordingly, the need exists for an annular support structure which operates in conjunction with any end-to-end, annular or circular stapling device and assists in maintaining the lumen of the anastomosed bowel or other tubular organ patent or open over time.


A need also exists for an annular support structure which operates in conjunction with any end-to-end, annular or circular stapling device to reduce the trauma suffered by the patient, reduce the instances of leakage, reduce the instances of bleeding, and create a relatively strong bond between adjacent body tissues.


A need also exists for an annular support structure configured to provide support to the anastomosed tissue, preferably, distally and/or proximally of the staple line.


SUMMARY

According to an aspect of the present disclosure, an apparatus for forming an anastomosis between adjacent intestinal sections of tissue is provided. The apparatus includes an anastomosis device having an anvil and a tubular body portion, wherein the anvil is selectively attachable to the tubular body portion by a shaft; and a support structure for deposition between the intestinal sections of tissue. The support structure includes a body defining an aperture therein for receiving the shaft. The body has an outer terminal edge. The support structure includes at least one layer of expandable material disposed at the outer terminal edge of the body.


The at least one layer of expandable material may include a first and a second membrane extending radially outward from the outer terminal edge of the body.


The aperture may be defined by an inner terminal edge of the body. The inner terminal edge may be disposed radially inward of staple receiving slots of a staple cartridge assembly disposed in the tubular body.


It is envisioned that each of the first and second membranes is made from a polymeric film, such as, for example, polyethylene. The support structure has an undeployed condition wherein the first and second membranes are rolled-up towards the body, and a deployed condition wherein the first membrane extends in a substantially distal direction from the body and the second membrane extends in a substantially proximal direction from the body.


The apparatus may further include a rip-cord for expanding the first and second membranes. The rip-cord is rolled-up into each of the first and second membranes when the support structure is in the undeployed condition.


Each membrane may include a first inner layer and a second outer layer. The second outer layer of each membrane may swell at a rate greater than the first inner layer. The second outer layers of the first and second membranes are made from a hydrogel. The first inner layer of each of the first and second membranes may be constructed from a substantially non-absorbable material. The first inner layer of each of the first and second membranes may be fabricated from a bio-absorbable mesh fabric.


According to another aspect of the present disclosure, a method of disposing a support structure between adjacent intestinal sections is provided. The method includes the step of providing a circular surgical anastomosis device. The circular surgical anastomosis device includes an anvil assembly having an anvil member and a first shaft; and a tubular body portion having an annular knife operatively disposed therein and a second shaft disposed radially inward of the annular knife, the first shaft of the anvil assembly being selectively attachable to the second shaft of the tubular body.


The method further includes the steps of inserting the anvil assembly into a first intestinal section; inserting the tubular body portion into a second intestinal section; disposing a support structure between the first intestinal section and the second intestinal section, the support structure having at least one layer of expandable material; approximating the anvil assembly and tubular body portion with one another so that an end portion of the first intestinal section, the support structure, and an end portion of the second intestinal section are disposed between the anvil member and the tubular body portion, the support structure being disposed between the first intestinal section and the second intestinal section; firing the surgical anastomosis device to sever the portions of the first and second intestinal sections disposed radially inward of the annular knife, and to touch the portions of the first and second intestinal sections radially outward of the annular knife against the structure; and expanding the at least one layer of expandable material.


The anvil assembly may include a first shaft and the tubular body portion includes a second shaft disposed radially inward of the annular knife. Desirably, the first shaft of the anvil member is attachable to the second shaft of the tubular body portion. Accordingly, the method may further include the step of attaching the first shaft of the anvil assembly to the second shaft of the tubular body portion prior to the step of approximating the anvil assembly to the tubular body portion.


The support structure may include an aperture formed therein. Accordingly, the method may further include the step of inserting one of the first shaft of the anvil assembly and the second shaft of the tubular body portion into the aperture of the support structure prior to the step of attaching the first shaft of the anvil assembly to the second shaft of the tubular body portion.


The tubular body portion may carry a plurality of surgical staples. The surgical staples may be disposed radially outward of the annular knife. Accordingly, in use, firing the surgical anastomosis device includes deploying the plurality of staples so that the staples penetrate a first interstitial section, the support structure and then a second interstitial section.


The support structure may include a body and a first and a second membrane extending radially outward from the body. Each of the first and second membranes of the support structure may be made from a polymeric film, such as, for example, polyethylene.


In use, expanding the at least one layer of expandable material may include deploying the first and second membranes from a rolled-up condition to an expanded condition. In the expanded condition, the first membrane may extend in a substantially distal direction from the body portion of the support structure and the second membrane may extend in a substantially proximal direction from the body portion of the support structure.


The method may further include the step of pulling on at least one rip-cord to expand the first and second membranes.


Each membrane of the support structure may include a first inner layer and a second outer layer. Accordingly, expanding the at least one layer may include expanding the second outer layer at a greater rate than the first inner layer. The second outer layer of each membrane of the support structure may swell at a rate greater than the first inner layer.


The second outer layers of the first and second membranes may be made from a hydrogel. The first inner layer of each of the first and second membranes of the support structure may be constructed from a substantially non-absorbable material. The first inner layer of each of the first and second membranes may be fabricated from a bio-absorbable mesh fabric. The body may be perforated or porous.


The at least one layer of expandable material may expand upon fluid absorption.


The body may be fabricated from at least one of a polyglactic material, a glycolide homopolymer, and a synthetic absorbable lactomer 9-1 material. The body may be a mesh or other fabric.


The body may include a wound treatment material. The wound treatment material is desirably at least one of an adhesive, a sealant, a hemostat, and a medicament.


The body may be compressible so that the outer terminal edge of the body extends beyond the outer radial surface of the anvil and tubular body portion. Accordingly, the body may be fabricated from foam. The body has a first thickness greater than one quarter of a diameter of the body.


The support structure has an unhydrated condition wherein the body has a first diameter and a first thickness, and a hydrated condition wherein the body has a second diameter greater than the first diameter and a second thickness greater than the first thickness. The body desirably expands from the first diameter and the first thickness to a second diameter and a second thickness upon application of a fluid thereto.


The body may be constructed from a first part of a two-part wound treatment material, and the fluid applied thereto is a second part of the two-part wound treatment material.


According to yet another aspect of the present disclosure, a method of performing a surgical anastomosis procedure is provided. The method includes the steps of providing an anastomosis apparatus having an anvil assembly movably mounted with respect to a tubular body portion; providing a support structure including a body having an outer terminal edge, and an aperture therethrough, the body being compressible; disposing an anvil assembly into a first intestinal section; disposing a distal end portion of the surgical stapling apparatus in a second intestinal section; positioning the support structure on a shaft of the anvil assembly; approximating the anvil assembly and the tubular body portion to capture the body of the support structure between the first intestinal section and the second intestinal section and to compress the body portion therebetween so that the body extends radially beyond the anvil member and the tubular body portion to seal the perimeter of the anastomosis site; and firing the anastomosis apparatus to join the first intestinal section, support structure, and second intestinal section.


The support structure may have an unhydrated condition wherein the body has a first diameter and a first thickness, and a hydrated condition wherein the body has a second diameter greater than the first diameter and a second thickness greater than the first thickness. The support structure may be pre-mounted onto the shaft of the anvil assembly prior to positioning of the anvil assembly in the first intestinal section. Accordingly, prior to approximating the anvil assembly and the tubular body portion, the method further includes the step of hydrating the support structure to expand the body from the first diameter and the first thickness to a second diameter and a second thickness.


The body may be constructed from a first part of a two-part wound treatment material, and the fluid applied thereto is a second part of the two-part wound treatment material.





BRIEF DESCRIPTION OF DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the disclosure and, together with a general description of the disclosure given above and the detailed description of the embodiments given below, serve to explain the principles of the disclosure, wherein:



FIG. 1 is a perspective view of an exemplary annular surgical stapling device;



FIG. 2 is a perspective view of a support structure in accordance with an embodiment of the present disclosure, shown in an undeployed condition;



FIG. 3 is a cross-sectional view of the support structure of FIG. 2, as taken through 3-3 of FIG. 2;



FIG. 4 is a perspective view of the support structure of FIGS. 2 and 3, shown in a deployed condition;



FIG. 5 is a cross-sectional view of the support structure of FIG. 4, shown in the deployed condition;



FIG. 6 is a perspective view of the intestinal area of a patient, illustrating a method of positioning the support structure of FIGS. 2-5 on the anvil rod of the annular stapling device of FIG. 1;



FIG. 7 is a schematic perspective view of the intestinal area of FIG. 6, illustrating the anvil rod mounted to the annular stapling device and having the support structure of FIGS. 2-5 disposed therebetween;



FIG. 8 is a longitudinal cross-sectional view illustrating the anvil rod mounted to the annular stapling device within a surgical site and the support structure of FIGS. 2-5, in an undeployed condition, disposed between the apposed surfaces of the tissue;



FIG. 9 is a longitudinal cross-sectional view illustrating the anvil rod mounted to the annular stapling device within a surgical site and the support structure of FIGS. 2-5, in a deployed condition, disposed between the apposed surfaces of the tissue;



FIG. 10 is a perspective view of an support structure according to an alternate embodiment of the present disclosure;



FIG. 11 is a cross-sectional view of the support structure of FIG. 10, as taken through 11-11 of FIG. 10;



FIG. 12 is an enlarged view of the indicated area of detail of FIG. 11;



FIG. 13 is a longitudinal cross-sectional view illustrating the anvil rod mounted to the annular stapling device within a surgical site and the support structure of FIGS. 10-12, in an undeployed condition, disposed between the apposed surfaces of the tissue;



FIG. 14 is a longitudinal cross-sectional view illustrating the anvil rod mounted to the annular stapling device within a surgical site and the support structure of FIGS. 10-12, in a deployed condition, disposed between the apposed surfaces of the tissue;



FIG. 15 is a perspective view of a support structure according to yet another alternate embodiment of the present disclosure;



FIG. 16 is a schematic perspective view of an anvil assembly of the annular stapling device of FIG. 1 including yet another support structure operatively associated therewith and in an unexpanded condition;



FIG. 17 is a schematic side elevational view of the anvil assembly of FIG. 16 illustrating the support structure in an expanded condition;



FIG. 18 is a perspective view of a support structure in accordance with another embodiment of the present disclosure, for use with the annular surgical stapling device of FIG. 1;



FIG. 19 is a cross-sectional view of the support structure of FIG. 18, as taken through 19-19 of FIG. 18;



FIG. 20 is a longitudinal cross-sectional view of the intestinal area of the patient following placement of the support structure of FIGS. 18 and 19 and firing of the surgical stapling apparatus;



FIG. 21 is an enlarged cross-sectional view, of the indicated area of detail of FIG. 20;



FIG. 22 is an enlarged cross-sectional view, of the indicated area of detail of FIG. 20, illustrating the annular support structure in a first condition;



FIG. 23 is an enlarged cross-sectional view, of the indicated area of detail of FIG. 20, illustrating the annular support structure in a second condition;



FIG. 24 is a perspective view of a support structure according to an alternate embodiment of the present disclosure;



FIG. 25 is a transverse cross-sectional view of the support structure of FIG. 24, as taken through 25-25 of FIG. 10;



FIG. 26 is a perspective view of the intestinal area of the patient, illustrating the positioning of the support structure of FIGS. 24 and 25 between the anvil assembly and the tubular body portion;



FIG. 27 is a longitudinal cross-sectional view of the intestinal area of the patient illustrating the intestinal sections approximated toward one another to contact the support structure of FIGS. 24 and 25;



FIG. 28 is a longitudinal cross-sectional view of the intestinal area of the patient illustrating the intestinal sections approximated toward one another to compress the support structure of FIGS. 24 and 25 between the intestinal sections;



FIG. 29 is a side elevational view of an anvil assembly including the support structure of FIGS. 24 and 25, in an unexpanded condition, operatively secured to the stem thereof; and



FIG. 30 is a side elevational view of an anvil assembly including the support structure of FIGS. 24 and 25, in an expanded condition, operatively secured to the stem thereof.





DETAILED DESCRIPTION OF EMBODIMENTS

Embodiments of the presently disclosed annular adhesive structures will now be described in detail with reference to the drawing figures wherein like reference numerals identify similar or identical elements. As used herein and as is traditional, the term “distal” refers to that portion which is furthest from the user while the term “proximal” refers to that portion which is closest to the user.


Referring initially to FIG. 1, an annular surgical stapling device, for use with the annular adhesive structures disclosed herein, is generally designated as 10. Surgical stapling device 10 includes a handle assembly 12 having at least one pivotable actuating handle member 14, and an advancing member 16. Extending from handle member 12, there is provided a tubular body portion 20 which may be constructed so as to have a curved shape along its length. Body portion 20 terminates in a staple cartridge assembly 22 which includes a pair of annular arrays of staple receiving slots 36 having a staple (not shown) disposed in each one of staple receiving slots 36. Positioned distally of staple cartridge assembly 22 there is provided an anvil assembly 30 including an anvil member 26 and a shaft 28 operatively associated therewith for removably connecting anvil assembly 30 to a distal end portion or connection member 40 of stapling device 10.


Staple cartridge assembly 22 may be fixedly connected to the distal end of tubular body portion 20 or may be configured to concentrically fit within the distal end of tubular body portion 20. Typically, staple cartridge assembly 22 includes a staple pusher (not shown) including a proximal portion having a generally frusto-conical shape and a distal portion defining two concentric rings of peripherally spaced fingers (not shown), each one of which is received within a respective staple receiving slot 36.


Typically, a knife (not shown), substantially in the form of an open cup with the rim thereof defining a knife edge, is disposed within staple cartridge assembly 22 and mounted to a distal surface of a staple pusher (not shown). The knife edge is disposed radially inward of the pair of annular arrays of staples. Accordingly, in use, as the staple pusher is advanced, the knife is also advanced axially outward.


Reference may be made to U.S. Pat. No. 5,915,616 to Viola et al., the entire content of which is incorporated herein by reference, for a detailed discussion of annular stapling device 10.


Turning now to FIGS. 2-9, an annular adhesive or support structure, in accordance with an embodiment of the present disclosure, is generally designated as 100. Structure 100 includes a washer-like or disk-like body 102 including a substantially centrally located aperture 104 formed therethrough. Structure 100 is defined by an outer terminal edge 106, an inner terminal edge 108 defining the size of aperture 104, an upper surface 110, and a bottom surface 112.


In one embodiment, structure 100 is sized such that when structure 100 is operatively associated with stapling device 10, as will be described in greater detail below, outer terminal edge 106 extends radially beyond staple retaining pockets 36 of staple cartridge assembly 22. Additionally, aperture 104 of structure 100 is sized to at least receive shaft 28 of anvil assembly 30 therethrough. In another embodiment, the distance between outer terminal edge 106 and inner terminal edge 108 is substantially equal to a width of a tissue contact surface 24 (see FIG. 1) of staple cartridge assembly 22.


It is contemplated that body 102 of structure 100 may be fabricated from or include a surgical grade, biocompatible, non-absorbable (i.e., permanent) mesh or material desirably impregnated with an adhesive, sealant and/or other medicament. For example, body 102 may be fabricated from “TEFLON”, which is a registered trademark owned by DuPont de Nemours & Co. It is further contemplated that body 102 may be fabricated from a biocompatible polymeric foam, felt, polytetrafluoroethylene (ePTFE), gelatin, fabric or the like, or any other biocompatible material.


Non-absorbable materials used for body 102 include, and are not limited to, those that are fabricated from such polymers as polyethylene, polypropylene, nylon, polyethylene terephthalate, polytetrafluoroethylene, polyvinylidene fluoride, and the like. Further non-absorbable materials include and are not limited to stainless steel, titanium and the like.


In one embodiment, body 102 of structure 100 may be fabricated from a bio-absorbable material which is desirably impregnated with an adhesive, sealant, and/or other medicament (i.e., wound treatment material). Accordingly, in use, the sealant component of structure 100 functions to retard any bleeding which may occur from the tissue, the adhesive component of structure 100 functions to secure the approximated tissue together, and the bio-absorbability of structure 100 allows for the at least a portion of structure 100 to be absorbed into the body after a predetermined amount of time. For example, structure 100 may remain in place in the body for approximately 2-3 weeks in order for the anastomosis to sufficiently heal prior to structure 100 being absorbed into the body.


Bio-absorbable materials used for body 102 of structure 100 include, and are not limited to, those fabricated from homopolymers, copolymers or blends obtained from one or more monomers selected from the group consisting of glycolide, glycolic acid, lactide, lactic acid, p-dioxanone, α-caprolactone and trimethylene carbonate. Other bio-absorbable materials include and are not limited to, for example, Polyglycolic Acid (PGA) and Polylactic Acid (PLA). In one embodiment, body 102 may be fabricated from bio-absorbable felt, ePTFE, gelatin or any other bio-absorbable materials. Illustrative examples of bioabsorbable materials include DEXON™ mesh, absorbable felts, such as POLYSORB™, and foams, such as polyurethane.


It is envisioned that body 102 of structure 100 may be impregnated with a wound treatment material “W” which is a pre-cured adhesive or sealant. The pre-cured sealant or adhesive will react with the moisture and/or heat of the body tissue to thereby activate the sealing and/or adhesive properties of the sealant or adhesive. It is envisioned that the pre-cured sealant or adhesive may be a hydro-gel or the like.


It is contemplated that the wound treatment material “W” is any material for joining, healing, sealing or otherwise treating tissue. In a preferred embodiment, the wound treatment material is a bio-compatible sealant, including, and not limited, to sealants which cure upon tissue contact, sealants which cure upon exposure to ultraviolet (UV) light, sealants which are two-part systems which are kept isolated from one another and are combined or any combinations thereof. Any known suitable adhesive may be used. In one embodiment, it is contemplated that such sealants and/or adhesives are curable. For example, sealants may have a cure time of from about 10 to 15 seconds may be used. In preferred embodiments, the sealant and/or adhesive is a bioabsorbable and/or bio-resorbable material. In another embodiment, it is contemplated that a sealant and/or adhesive having a cure time of about 30 seconds may be used. It is further envisioned that wound treatment material “W” may be a pre-cured adhesive or sealant.


In certain preferred embodiments, the wound treatment material comprises a sealant. Such a sealant is desirably a PEG-based material. Examples of classes of materials useful as the sealant and/or adhesive include acrylate or methacrylate functional hydrogels in the presence of a biocompatible photoinitiator, alkyl-cyanoacrylates, isocyanate functional macromers with or without amine functional macromers, succinimidyl ester functional macromers with amine or sulfhydryl functional macromers, epoxy functional macromers with amine functional macromers, mixtures of proteins or polypeptides in the presence of aldehyde crosslinkers, Genipin, or water-soluble carbodiimides, anionic polysaccharides in the presence of polyvalent cations, etc.


Some specific materials which may be utilized include isocyanate terminated hydrophilic urethane prepolymers derived from organic polyisocyanates and oxyethylene-based diols or polyols, including those disclosed in U.S. Pat. Nos. 6,702,731 and 6,296,607 and U.S. Published Patent Application No. 2004/0068078; alpha-cyanoacrylate based adhesives including those disclosed in U.S. Pat. No. 6,565,840; alkyl ester based cyanoacrylate adhesives including those disclosed in U.S. Pat. No. 6,620,846; adhesives based on biocompatible cross-linked polymers formed from water soluble precursors having electrophilic and nucleophilic groups capable of reacting and cross-linking in situ, including those disclosed in U.S. Pat. No. 6,566,406; two part adhesive systems including those based upon polyalkylene oxide backbones substituted with one or more isocyanate groups in combination with bioabsorbable diamine compounds, or polyalkylene oxide backbones substituted with one or more amine groups in combination with bioabsorbable diisoycanate compounds as disclosed in U.S. Published Patent Application No. 2003/0032734, the contents of which are incorporated by reference herein; and isocyanate terminated hydrophilic urethane prepolymers derived from aromatic diisocyanates and polyols as disclosed in U.S. Published Patent Application No. 2004/0115229, the contents of which are incorporated by reference herein.


It is envisioned and within the scope of the present disclosure that wound treatment material “W” may include one or a combination of adhesives, hemostats, sealants, or any other tissue or wound-treating material. Surgical biocompatible wound treatment materials “W”, which may be used in accordance with the present disclosure, include adhesives whose function is to attach or hold organs, tissues or structures, sealants to prevent fluid leakage, and hemostats to halt or prevent bleeding. Examples of adhesives which can be employed include protein derived, aldehyde-based adhesive materials, for example, the commercially available albumin/glutaraldehyde materials sold under the trade designation BioGlue™ by Cryolife, Inc., and cyanoacrylate-based materials sold under the trade designations Indermil™ and Derma Bond™ by Tyco Healthcare Group, LP and Ethicon Endosurgery, Inc., respectively. Examples of sealants, which can be employed, include fibrin sealants and collagen-based and synthetic polymer-based tissue sealants. Examples of commercially available sealants are synthetic polyethylene glycol-based, hydrogel materials sold under the trade designation CoSeal™ by Cohesion Technologies and Baxter International, Inc. Examples of hemostat materials, which can be employed, include fibrin-based, collagen-based, oxidized regenerated cellulose-based and gelatin-based topical hemostats. Examples of commercially available hemostat materials are fibrinogen-thrombin combination materials sold under the trade designations CoStasis™ by Tyco Healthcare Group, LP, and Tisseel™ sold by Baxter International, Inc. Hemostats herein include astringents, e.g., aluminum sulfate, and coagulants.


The medicament may include one or more medically and/or surgically useful substances such as drugs, enzymes, growth factors, peptides, proteins, dyes, diagnostic agents or hemostasis agents, monoclonal antibodies, or any other pharmaceutical used in the prevention of stenosis. The medicament may be disposed on structure 100 or impregnated into structure 100. The medicament may include one or more medically and/or surgically useful substances such as drugs, enzymes, growth factors, peptides, proteins, dyes, diagnostic agents or hemostasis agents, monoclonal antibodies, or any other pharmaceutical used in the prevention of stenosis.


Wound treatment material “W” may include visco-elastic film forming materials, cross-linking reactive agents, and energy curable adhesives. It is envisioned that wound treatment material “W”, and in particular, adhesive may be cured with the application of water and/or glycerin thereto. In this manner, the water and/or glycerin cure the adhesive and hydrate the wound.


It is further contemplated that wound treatment material “W” may include, for example, compositions and/or compounds which accelerate or beneficially modify the healing process when particles of the composition and/or compound are applied to or exposed to a surgical repair site. For example, the wound treatment material “W” may be a therapeutic agent which will be deposited at the repair site. The therapeutic agent can be chosen for its antimicrobial properties, capability for promoting repair or reconstruction and/or new tissue growth. Antimicrobial agents such as broad spectrum antibiotic (gentamycin sulfate, erythromycin or derivatized glycopeptides) which are slowly released into the tissue can be applied in this manner to aid in combating clinical and sub-clinical infections in a tissue repair site. To promote repair and/or tissue growth, wound treatment material “W” may include one or several growth promoting factors, e.g., fibroblast growth factor, bone growth factor, epidermal growth factor, platelet derived growth factor, macrophage derived growth factor, alveolar derived growth factor, monocyte derived growth factor, magainin, and so forth. Some therapeutic indications are: glycerol with tissue or kidney plasminogen activator to cause thrombosis, superoxide dimutase to scavenge tissue damaging free radicals, tumor necrosis factor for cancer therapy or colony stimulating factor and interferon, interleukin-2 or other lymphokine to enhance the immune system.


In one embodiment, it is contemplated that body 102 of structure 100 may be impregnated with a first component of a two-part adhesive and that the staples, retained in staple receiving slots 36 of staple cartridge assembly 22, may be coated with a second component (e.g., a reactant) of the two-part adhesive. In this manner, the first component of the adhesive is activated when the staples penetrate and capture body 102 of structure 100 during the firing sequence of surgical stapling device 10, and the two components of the adhesive contact one another.


As seen in FIGS. 2-9, in an embodiment annular support structure 100 includes at least one, preferably a pair of drapes, skirts or membranes 140, 142 (e.g., a first membrane 140 and a second membrane 142) extending from outer terminal edge 106 of body 102. Desirably, membranes 140, 142 are fabricated from a polymeric or plastic film including and not limited to polyethylene and the like. Each membrane 140, 142 includes a first or outer surface 140a, 142a, respectively, and a second or inner surface 140b, 142b, respectively.


As seen in FIGS. 2 and 3, membranes 140, 142 have a first, undeployed condition wherein membranes 140, 142 are rolled-up towards body 102. Desirably, membranes 140, 142 are rolled under in a direction toward the first or outer surfaces 140a, 142a thereof, as indicated by arrows “A” of FIG. 3. As seen in FIGS. 4 and 5, membranes 140, 142 have a second, deployed condition wherein membranes 140, 142 are unrolled or unfurled to extend in a substantially parallel orientation with respect to the central “X” axis. As will be described in greater detail below, first membrane 140 is unrolled in a first direction, preferably in a distal direction (e.g., in a direction substantially orthogonal to upper surface 110 of body 102), and second membrane 142 is unrolled in a second direction, preferably in a proximal direction (e.g., in a direction substantially orthogonal to lower surface 112 of body 102).


As seen in FIGS. 2 and 3, support structure 100 desirably includes a rip-cord or tether 144, 146 rolled-up into membranes 140, 142. Rip-cords 144, 146 include free ends 144a, 146a which extend from membranes 140, 142 when membranes 140, 142 are in the rolled-up condition. In this manner, as will be described in greater detail below, as rip-cords 144, 146 are pulled, desirably in a distal direction (e.g., orthogonal to upper surface 110 of body 102) and a proximal direction (e.g., orthogonal to lower surface 112 of body 102), membranes 140, 142 are un-rolled or un-furled accordingly.


In one embodiment, it is envisioned that body 102 of support structure 100 is formed of a foam material overmolded onto a relatively thin flexible material or film making up membranes or sleeves 140, 142. Desirably, when un-rolled or un-furled, each membrane 140, 142 extends approximately 2.0 cm from body 102. In other words, when un-rolled or un-furled, first membrane 140 extends from body 102 by approximately 2.0 cm from upper surface 110 of body 102, and second membrane 142 extends from body 102 approximately 2.0 cm from lower surface 112 of body 102.


Turning now to FIGS. 6-9, there is illustrated the use of surgical stapling device 10 and support structure 100 in an anastomosis procedure to effect joining of intestinal sections 66 and 68. The anastomosis procedure is typically performed using minimally invasive surgical techniques including laparoscopic means and instrumentation. At the point in the procedure shown in FIG. 6, a diseased intestinal section has been previously removed, anvil assembly 30 has been introduced to the operative site either through a surgical incision or trans-anally and positioned within intestinal section 68, and tubular body portion 20 of surgical stapling device 10 has been inserted trans-anally into intestinal section 66. Intestinal sections 66 and 68 are also shown temporarily secured about their respective components (e.g., shaft 28 of anvil assembly 30, and the distal end of tubular body portion 20) by conventional means such as a purse string suture “P”.


Annular support structure 100 is then placed onto shaft 28 of anvil assembly 30 prior to the coupling of anvil assembly 30 to the distal end of tubular body portion 20. In particular, shaft 28 of anvil assembly 30 is inserted into aperture 104 of body portion 102. Following positioning of structure 100 onto shaft 28 of anvil assembly 30, the surgeon maneuvers anvil assembly 30 until the proximal end of shaft 28 is inserted into the distal end of tubular body portion 20 of surgical stapling device 10, wherein the mounting structure (not shown) within the distal end of tubular body portion 20 engages shaft 28 to effect the mounting.


Thereafter, as seen in FIG. 8, anvil assembly 30 and tubular body portion 20 are approximated to approximate intestinal sections 66, 68 and capture body 102 of annular support structure 100 therebetween. With body 102 captured between intestinal sections 66, 68, as seen in FIG. 9, membranes 140, 142 are deployed (i.e., un-rolled or un-furled) as described above. In particular, first membrane 140 is un-rolled or un-furled in a distal direction, as indicated by arrow “B”, so as to over-lie intestinal section 68, and second membrane 142 is un-rolled or un-furled in a proximal direction, as indicated by arrow “C”, so as to over-lie intestinal section 66. Desirably, first and second membranes 140, 142 are un-rolled or un-furled by pulling on rip-cords 144, 146 in a distal or proximal direction, as necessary.


Membranes 140, 142 extend a predetermined distance over intestinal sections 66 and 68 (e.g., approximately 2 cm). When un-rolled or un-furled, membranes 140, 142 will adhere to the surface of intestinal sections 66, 68. Membranes 140 and 142 function to inhibit leakage from the anastomosis site and/or function to strengthen or reinforce intestinal sections 66, 68. With membranes 140, 142 deployed, as seen in FIG. 15, surgical stapling device 10 may be fired thereby stapling intestinal sections 66, 68 to one another and cutting the portion of tissue and structure 100 disposed radially inward of the knife, to complete the anastomosis.


Turning now to FIGS. 10-14, annular support structure 100 includes at least one, preferably a pair of membranes 150, 152 (e.g., a first membrane 150 and a second membrane 152) extending from outer edge 106 of body 102. Each membrane 150 and 152 includes two layers, an inner layer 150a, 152a, respectively, and an outer layer 150b, 152b, respectively. Desirably, the materials selected for the construction of membranes 150, 152 swell at different rates when in the presence of moisture or fluid. In this manner, membranes 150, 152 will tend to bend or curl about the layer having the relatively slower rate of fluid swelling or fluid absorption. In this manner, support structure 100 has a first undeployed condition in which membranes 150, 152 extend substantially radially outward from body 102, and a second deployed condition in which membranes 150, 152 are substantially aligned with the central “X” axis of body 102.


In accordance with one embodiment, it is envisioned that inner layer 150a, 152a of membranes 150, 152 are constructed from a substantially non-absorbable (i.e., does not absorb moisture therein) or non-expanding (i.e., static) material, such as, for example, a bio-absorbable mesh fabricated from polyglycolic acid, sold under the tradename DEXON™, available from Tyco Healthcare Group LP, Norwalk, Conn. It is also envisioned that outer layer 150b, 152b of membranes 150, 152 are constructed from an absorbable or expanding (i.e., dynamic) material, such as, for example, hydrogel and the like.


Desirably, each membrane 150 and 152 includes a hydrogel outer layer 150b, 152b laminated to a bio-absorbable mesh inner layer 150a, 152a. Furthermore, support structure 100 includes a foam body 102 laminated over a pair of dual layered membranes 150, 152. While each membrane 150, 152 desirably includes a pair of layers, it is envisioned and within the scope of the present disclosure for membranes 150, 152 to include any number of layers.


Accordingly, with reference to FIG. 12, the difference in material properties between inner layers 150a, 152a and outer layers 150b, 152b of membranes 150, 152 cause membranes 150, 152 to curl or bend from the undeployed condition, wherein membranes 150, 152 extend in a substantially radial direction, to a deployed condition, wherein membranes 150, 152 extend in a direction substantially parallel to the central “X” axis (as shown in phantom in FIG. 12).


Turning now to FIGS. 13 and 14, there is illustrated the use of surgical stapling device 10 and support structure 100 including membranes 150, 152 in an anastomosis procedure to effect joining of intestinal sections 66 and 68. At the point in the procedure shown in FIG. 13, anvil assembly 30 and tubular body portion 20 are shown approximated to one another to capture body 102 of annular support structure 100 between intestinal sections 66 and 68, wherein intestinal section 66 and 68 were previously secured about their respective components (e.g., shaft 28 of anvil assembly 30, and the distal end of tubular body portion 20) by conventional means such as a purse string suture “P”, annular support structure 100 was positioned between intestinal sections 66 and 68, and anvil assembly 30 was coupled to the distal end of tubular body portion 20.


With body portion 102 of support structure 100 captured between intestinal sections 66, 68, as seen in FIGS. 13 and 14, membranes 150, 152 begin to deploy (i.e., curl or bend from the substantially radially extended orientation to the orientation substantially parallel with the central “X” axis) as described above. In particular, as outer layers 150b, 152b of first and second membranes 150, 152 absorb fluid and swell (i.e., expand), first and second membranes 150, 152 curl or bend to the side of membrane 150, 152 which swells or expands at a rate slower, i.e., toward inner layers 150a, 152a. As membranes 150, 152 are deployed, as indicated by arrow “B”, first membrane 150 over-lies intestinal section 68, and second membrane 152 over-lies intestinal section 66, as indicated by arrow “C”.


Desirably, membranes 150, 152 extend a predetermined distance over intestinal sections 66 and 68 (e.g., approximately 2 cm). Accordingly, when deployed, membranes 150, 152 will adhere to the surface of intestinal sections 66, 68. Membranes 150, 152 function to inhibit leakage from the anastomosis site and/or function to strengthen or reinforce intestinal sections 66, 68. With membranes 150, 152 deployed, as seen in FIG. 14, surgical stapling device 10 may be fired thereby stapling intestinal sections 66, 68 to one another and cutting the portion of tissue and structure 100 disposed radially inward of the knife, to complete the anastomosis.


As seen in FIG. 15, annular support structure 100 includes a series of ribs 156, 158 provided on and/or in each membrane 150, 152, respectively. Desirably, ribs 156, 158 extend radially around the perimeter or circumference of membranes 150, 152. Ribs 156, 158 are substantially radially oriented.


Ribs 156, 158 are fabricated from a shape memory material, alloy or the like, preferably, NITINOL™ and the like. It is further envisioned that ribs 156, 158 may be fabricated from a bio-absorbable material.


Ribs 156, 158 have a memorized shape which is oriented substantially parallel to the central “X” axis of support structure 100. In this manner, support structure 100 has a first or un-deployed condition in which ribs 156, 158 are in a biased rolled-up condition and membranes 150, 152 are also rolled-up, and a second or deployed condition in which ribs 156, 158 are in their memorized shape or condition and membranes 150, 152 are extended.


In use, with support structure in an un-deployed condition, support structure 100 is positioned in shaft 28 of anvil assembly 30. With support structure 100 so positioned, support structure 100 is deployed when ribs 156, 158 return to their memorized conditions. In particular, the return of ribs 156, 158 to their memorized conditions extends membranes 150, 152 over intestinal sections 66 and 68 and/or in a direction substantially parallel to the central “X” axis.


Turning now to FIGS. 18-28, a support structure in accordance with an alternate embodiment is generally designated as 200. Support structure 200 is substantially similar to support structure 100 and will only be described in detail to the extent necessary to identify differences in construction and operation.


As seen in FIGS. 18 and 19, body 202 of support structure 200 includes a plurality of pores 214 extending therethrough. Desirably, pores 214 are substantially parallel with the longitudinal “X” axis of body 202. Pores 214 allow for healing to take place between a pair of apposed tissue surfaces. Additionally, since pores 214 are substantially parallel to the longitudinal “X” axis, leakage of fluid from the anastomotic site is reduced. While body 202 has been shown and described as including pores 214, it is envisioned and within the scope of the present disclosure that body 202 may be perforated or may be constructed from a porous material.


With continued reference to FIGS. 18 and 19, support structure 200 includes a rim or layer 220 of fluid expanding or water-swellable material, e.g., a hydrogel, disposed around outer terminal edge 206 of body 202. Hydrogels contemplated for support structure 200 are identified in U.S. Pat. No. 5,505,952 to Jiang et al., the entire content of which is incorporated herein by reference.


Turning now to FIGS. 20-23, there is illustrated the use of support structure 200 in an anastomosis procedure to effect joining of intestinal sections 66 and 68. The anastomosis procedure is typically performed using minimally invasive surgical techniques including laparoscopic means and instrumentation. At the point in the procedure shown in FIG. 20, support structure 200 has been placed onto shaft 28 of anvil assembly 30, the anvil assembly 30 has been coupled to the distal end of tubular body portion 20 of surgical stapling device 10, and surgical stapling device 10 has been fired thereby stapling intestinal sections 66, 68 to one another and cutting the portion of tissue and support structure 200 disposed radially inward of the knife, to complete the anastomosis.


As seen in FIG. 21, pores 214 of body 202 allow for in-growth of intestinal sections 66, 68 therein thereby improving the healing process. In particular, pores 214 of body 202 reduce the time required for intestinal sections 66, 68 to contact one another during the healing process. For example, depending on the size of pores 214 of body 202, intestinal sections 66, 68 may contact one another immediately following the firing of surgical stapling device 10, or pores 214 of body 202 define channels into which intestinal sections 66, 68 may grow and come into contact with one another over time.


As seen in FIG. 22, initially, following placement of support structure 200 into position between intestinal sections 66, 68 and firing of surgical stapling device 10, rim 220 of support structure 200 is in a first or unexpanded (i.e., un-swelled) condition. Subsequently, as seen in FIG. 23, with support structure 200 in position between intestinal sections 66, 68, rim 220 thereof begins to absorb moisture from the surrounding environment (e.g., water, saline, blood, etc.) and expand to a second or swelled condition. In one method, it is envisioned that fluid may be dispensed onto the anastomosis site, especially onto rim 220 of support structure 200 in order to cause expanding and/or swelling of rim 220.


As seen in FIG. 23, as rim 220 of support structure 200 swells or expands, the radial gap “G” between intestinal sections 66, 68 fills. Accordingly, rim 220, when in the swelled or expanded condition acts as a seal, dam, stopper, barrier or the like to inhibit and/or prevent the leakage of the contents of the bowel into the abdominal region of the patient. In other words, the swelling of rim 220 results in the formation of a gasket-like seal around the outside of the anastomosis.


Turning now to FIGS. 24-28, a support structure, in accordance with an alternate embodiment of the present disclosure, is generally designated as 300. As seen in FIGS. 24 and 25, body 302 of support structure 300 may be formed entirely of resilient compressible foam or sponge-like material fabricated from a bio-absorable material or any other bio-compatible material disclosed above with regard to support structure 100. Desirably, as seen in FIG. 25, body 302 of support structure 300 has an initial height or thickness “T1” (e.g., the height or thickness when body 302 is fully expanded). Desirably, body 302 has a diameter “D” which is at least equal to a diameter of tubular body portion 20 and/or anvil member 26. Most desirably, the diameter “D” of body portion of support structure 300 is greater than the diameters of tubular body 20 and/or anvil member 26. Desirably, thickness “T1” is greater than a quarter of the diameter “D”, when in the initial uncompressed condition.


Turning now to FIGS. 26-28, there is illustrated the use of surgical stapling device 10 and support structure 300 in an anastomosis procedure to effect joining of first and second tissue sections or intestinal sections 66 and 68. As seen in FIGS. 27 and 28, with a support structure 300 positioned on shaft 28 of anvil assembly 30 and disposed between intestinal sections 66, 68, as anvil assembly 30 and tubular body portion 20 are approximated, body 302 of support structure 300 is compressed therebetween. In particular, as seen in FIG. 27, prior to complete approximation, body 302 of support structure 300 is uncompressed and desirably extends radially beyond the outer terminal edges of tubular body portion 20 and/or anvil member 26. In particular, body 302 of support structure 300 has a thickness substantially equal to “T1”. Thereafter, upon complete approximation, body 302 of support structure 300, in the region disposed between tubular body portion 20 and anvil member 26, is compressed therebetween to a thickness “T2”. Accordingly, the portion of support structure 300 disposed radially outward of tubular body portion 20 and anvil member 26 remains substantially uncompressed (e.g., having a thickness approximately equal to “T1”) thereby filling and/or sealing the radial gap “G” between intestinal sections 66, 68.


In addition to reducing leakage from the anastomosis site, due to the compressible nature of body 302 of support 300, the body 302 is capable of filling any voids or recesses which may exist in the surface of intestinal sections 66, 68.


Following the approximation of anvil assembly 30 and tubular body portion 20, to approximate intestinal sections 66, 68 and capture body 302 of support structure 300 therebetween, surgical stapling device 10 is fired thereby stapling intestinal sections 66, 68 to one another and cutting the portion of tissue and support structure 300 disposed radially inward of the knife, to complete the anastomosis.


As seen in FIG. 29, support structure 300 may have an unexpanded (e.g., collapsed or un-hydrated condition) in which body 302 of support structure 300 has a first diameter “D1” and a first thickness “T1”. Additionally, as seen in FIGS. 29 and 30, anvil assembly 30 includes a network of channels 28a formed in shaft 28 which are configured and arranged to dispense fluid onto and/or direct fluid into body 302 of support structure 300. While channels 28a have been shown and described, any structure for delivering fluid to body 302 of support structure 300 is contemplated by the present disclosure.


As seen in FIG. 30, fluid “F” is delivered to body 302 of support structure 300 thereby causing body 302 of support structure 300 to expand radially and longitudinally. In other words, the application of fluid “F” to body 302 of support structure 300 causes body 302 of support structure 300 to expand and hydrate. In the expanded condition, body 302 of support structure 300 has a second diameter “D2”, larger than first diameter “D1”, and a second thickness “T2”, larger than first thickness “T1”.


In use, with support structure 300 in the un-expanded condition, anvil assembly 30 is introduced into the surgical site as described above. Following connection of anvil assembly 30 to the distal end of tubular body portion 20, fluid “F” is delivered to body 302 of support structure 300, thereby causing support structure 300 to expand. Following expansion of support structure 300, the surgical procedure is continued as described above.


It is envisioned and within the scope of the present disclosure that the fluid “F” may be a cross-linker or other substance which is reactive with the foam of body 302 of support structure 300 to thereby form or create a support structure 300 of wound treatment material (e.g., adhesive, sealant, hemostat, medicament, etc.). It is contemplated that body 302 of support structure 300 may be a foam made from a first part of a two-part wound treatment material, and fluid “F” may include a second part of the two-part wound treatment material. In this manner, the wound treatment material is formed upon interaction of fluid “F” with body 302 of support structure 300.


From the foregoing, it will be appreciated that the support structures of the present disclosure function to strengthen the anastomosis and reduce the occurrence of bleeding, leaking and stricture. It is also to be appreciated that the support structures of the present disclosure may be utilized in a number of other applications and is not limited solely to bowel or bronchus anastomosis.


While several particular forms of the support structures have been illustrated and described, it will also be apparent that various modifications can be made without departing from the spirit and scope of the present disclosure. For example, it is envisioned and within the scope of the present disclosure for an ultraviolet light activated adhesive to be used in connection with any of the support structures described above. In use, either prior to or following firing of surgical stapling device 10, the support structure is irradiated with UV light to thereby activate the adhesive thereof.


It is further contemplated that each of the support structures described herein may be used with an annular surgical anastomosing device, not including any staples for securing tissue together, which is capable of approximating, adhering and cutting tissue.


Thus, it should be understood that various changes in form, detail and application of the support structures of the present disclosure may be made without departing from the spirit and scope of the present disclosure.

Claims
  • 1. A method of performing an anastomosis between tissue sections, comprising: introducing an anvil assembly of a surgical stapling device into a first tissue section, the anvil assembly including an anvil member and a shaft;positioning a support structure on the shaft of the anvil assembly in an unexpanded condition, the support structure including a body having an outer terminal edge and an inner terminal edge defining an aperture through which the shaft of the anvil assembly is received;introducing a tubular body portion of the surgical stapling device into a second tissue section;coupling the anvil assembly to the tubular body portion; anddelivering fluid through the shaft of the anvil assembly and onto the body of the support structure, and hydrating the support structure to an expanded condition.
  • 2. The method according to claim 1, further comprising approximating the anvil assembly and the tubular body portion to capture the support structure between the first and second tissue sections.
  • 3. The method according to claim 2, wherein approximating the anvil assembly and the tubular body portion includes compressing the body of the support structure between the first and second tissue sections such that the outer terminal edge of the support structure extends radially beyond outer terminal edges of the anvil member and the tubular body portion.
  • 4. The method according to claim 3, wherein approximating the anvil assembly and the tubular body portion includes filling a radial gap between the first and second tissue sections with the outer terminal edge of the support structure which remains substantially uncompressed during compression of the body of the support structure between the first and second tissue sections.
  • 5. A method of performing an anastomosis between tissue sections, comprising: introducing an anvil assembly of a surgical stapling device into a first tissue section, the anvil assembly including an anvil member and a shaft positioning a support structure on the shaft of the anvil assembly, the support structure including a body having an outer terminal edge and an inner terminal edge defining an aperture through which the shaft of the anvil assembly is received, the support structure having a first diameter and a first thickness when positioned on the shaft of the anvil assembly; anddelivering fluid through the shaft of the anvil assembly and onto the body of the support structure, and expanding the support structure to a second diameter larger than the first diameter and a second thickness larger than the first thickness.
  • 6. The method according to claim 1, wherein the fluid is reactive with the body of the support structure to form a wound treatment material, and wherein delivering the fluid includes forming a wound treatment material.
  • 7. The method according to claim 6, wherein the support structure includes a first part of a multiple-part wound treatment material and the fluid applied thereto includes a second part of the multiple-part wound treatment material, and wherein forming the wound treatment material includes reacting the first and second parts of the multiple-part wound treatment material.
  • 8. The method according to claim 1, further comprising firing the surgical stapling device to staple the first and second tissue sections to each other and the support structure therebetween.
  • 9. The method according to claim 8, wherein firing the surgical stapling device includes cutting portions of the first and second tissue sections and the support structure disposed radially inward of an annular knife of the surgical stapling device.
  • 10. The method according to claim 1, wherein positioning the support structure on the shaft includes inserting the shaft through the aperture of the support structure.
  • 11. The method according to claim 1, wherein delivering the fluid includes dispensing the fluid through at least one channel formed in the shaft of the anvil assembly.
  • 12. A method of performing an anastomosis between tissue sections, comprising: introducing an anvil assembly of a surgical stapling device into a first tissue section, the anvil assembly including an anvil member and a shaft;positioning a support structure on the shaft of the anvil assembly with a body of the support structure positioned over at least one channel formed in the shaft, the body having an outer terminal edge and an inner terminal edge defining an aperture through which the shaft of the anvil assembly is received; anddelivering fluid through the shaft of the anvil assembly and onto the body of the support structure by dispensing the fluid through the at least one channel formed in the shaft of the anvil assembly.
  • 13. The method according to claim 1, wherein coupling the anvil assembly to the tubular body portion includes inserting a proximal end of the shaft of the anvil assembly into a distal end of the tubular body portion.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No. 15/201,875, filed on Jul. 5, 2016, which is a divisional of U.S. application Ser. No. 13/848,265, filed on Mar. 21, 2013, now U.S. Pat. No. 9,445,817, which is a continuation of U.S. application Ser. No. 13/076,550, filed on Mar. 31, 2011, now U.S. Pat. No. 8,424,742, which is a divisional of U.S. application Ser. No. 11/241,267, filed on Sep. 30, 2005, now U.S. Pat. No. 7,938,307, which claims the benefit of and priority to each of U.S. Provisional Application Ser. No. 60/620,066, filed Oct. 18, 2004, and U.S. Provisional Application Ser. No. 60/620,065, filed Oct. 18, 2004, the entire contents of each of which being incorporated herein by reference.

US Referenced Citations (778)
Number Name Date Kind
3054406 Usher Sep 1962 A
3079606 Bobrov et al. Mar 1963 A
3124136 Usher Mar 1964 A
3364200 Ashton et al. Jan 1968 A
3490675 Green et al. Jan 1970 A
3499591 Green Mar 1970 A
3797494 Zaffaroni Mar 1974 A
3937222 Banko Feb 1976 A
3939068 Wendt et al. Feb 1976 A
3948666 Kitanishi et al. Apr 1976 A
4064062 Yurko Dec 1977 A
4166800 Fong Sep 1979 A
4282236 Broom Aug 1981 A
4347847 Usher Sep 1982 A
4354628 Green Oct 1982 A
4416698 McCorsley, III Nov 1983 A
4429695 Green Feb 1984 A
4452245 Usher Jun 1984 A
4603693 Conta et al. Aug 1986 A
4605730 Shalaby et al. Aug 1986 A
4626253 Broadnax, Jr. Dec 1986 A
4655221 Devereux Apr 1987 A
4665917 Clanton et al. May 1987 A
4703887 Clanton et al. Nov 1987 A
4834090 Moore May 1989 A
4838884 Dumican et al. Jun 1989 A
4873977 Avant et al. Oct 1989 A
4927640 Dahlinder et al. May 1990 A
4930674 Barak Jun 1990 A
5002551 Linsky et al. Mar 1991 A
5014899 Presty et al. May 1991 A
5040715 Green et al. Aug 1991 A
5057334 Vail Oct 1991 A
5065929 Schulze et al. Nov 1991 A
5112496 Dhawan et al. May 1992 A
5156613 Sawyer Oct 1992 A
5156614 Green et al. Oct 1992 A
5162430 Rhee et al. Nov 1992 A
5205459 Brinkerhoff et al. Apr 1993 A
5254113 Wilk Oct 1993 A
5261920 Main et al. Nov 1993 A
5263629 Trumbull et al. Nov 1993 A
5281197 Arias et al. Jan 1994 A
5307976 Olson et al. May 1994 A
5309927 Welch May 1994 A
5312023 Green et al. May 1994 A
5314471 Brauker et al. May 1994 A
5318221 Green et al. Jun 1994 A
5318531 Leone Jun 1994 A
5324775 Rhee et al. Jun 1994 A
5326013 Green et al. Jul 1994 A
5332142 Robinson et al. Jul 1994 A
5344454 Clarke et al. Sep 1994 A
5346501 Regula et al. Sep 1994 A
5392979 Green et al. Feb 1995 A
5397324 Carroll et al. Mar 1995 A
5405072 Zlock et al. Apr 1995 A
5410016 Hubbell et al. Apr 1995 A
5425745 Green et al. Jun 1995 A
5441193 Gravener Aug 1995 A
5441507 Wilk Aug 1995 A
5443198 Viola et al. Aug 1995 A
5465896 Allen et al. Nov 1995 A
5468253 Bezwada et al. Nov 1995 A
5484913 Stilwell et al. Jan 1996 A
5503638 Cooper et al. Apr 1996 A
5505952 Jiang et al. Apr 1996 A
5514379 Weissleder et al. May 1996 A
5542594 McKean et al. Aug 1996 A
5543441 Rhee et al. Aug 1996 A
5549628 Cooper et al. Aug 1996 A
5550187 Rhee et al. Aug 1996 A
5554119 Harrison et al. Sep 1996 A
5575803 Cooper et al. Nov 1996 A
5588579 Schnut et al. Dec 1996 A
5611775 Machold et al. Mar 1997 A
5645915 Kranzler et al. Jul 1997 A
5653756 Clarke et al. Aug 1997 A
5669934 Sawyer Sep 1997 A
5683809 Freeman et al. Nov 1997 A
5690675 Sawyer et al. Nov 1997 A
5702409 Rayburn et al. Dec 1997 A
5735833 Olson Apr 1998 A
5749895 Sawyer et al. May 1998 A
5752965 Francis May 1998 A
5752974 Rhee et al. May 1998 A
5762256 Mastri et al. Jun 1998 A
5766188 Igaki Jun 1998 A
5769892 Kingwell Jun 1998 A
5782396 Mastri et al. Jul 1998 A
5799857 Robertson et al. Sep 1998 A
5810855 Rayburn et al. Sep 1998 A
5814057 Oi et al. Sep 1998 A
5819350 Wang Oct 1998 A
5824015 Sawyer Oct 1998 A
5833695 Yoon Nov 1998 A
5843033 Ropiak Dec 1998 A
5843096 Igaki et al. Dec 1998 A
5866561 Ungs Feb 1999 A
5871135 Williamson, IV et al. Feb 1999 A
5874500 Rhee et al. Feb 1999 A
5895412 Tucker Apr 1999 A
5895415 Chow et al. Apr 1999 A
5902312 Frater et al. May 1999 A
5908427 McKean et al. Jun 1999 A
5915616 Viola et al. Jun 1999 A
5931165 Reich et al. Aug 1999 A
5931847 Bittner et al. Aug 1999 A
5957363 Heck Sep 1999 A
5964394 Robertson Oct 1999 A
5964774 McKean et al. Oct 1999 A
5997895 Narotam et al. Dec 1999 A
6019791 Wood Feb 2000 A
6030392 Dakov Feb 2000 A
6032849 Mastri et al. Mar 2000 A
6045560 McKean et al. Apr 2000 A
6063097 Oi et al. May 2000 A
6080169 Turtel Jun 2000 A
6093557 Pui et al. Jul 2000 A
6099551 Gabbay Aug 2000 A
6142933 Longo et al. Nov 2000 A
6149641 Ungs Nov 2000 A
6149667 Hovland et al. Nov 2000 A
6152943 Sawhney Nov 2000 A
6155265 Hammerslag Dec 2000 A
6156677 Brown Reed et al. Dec 2000 A
6165201 Sawhney et al. Dec 2000 A
6179862 Sawhney Jan 2001 B1
6210439 Firmin et al. Apr 2001 B1
6214020 Mulhauser et al. Apr 2001 B1
6228051 Trumbull May 2001 B1
6241139 Milliman et al. Jun 2001 B1
6258107 Balazs et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6273897 Dalessandro et al. Aug 2001 B1
6280453 Kugel et al. Aug 2001 B1
6287323 Hammerslag Sep 2001 B1
6296607 Milbocker Oct 2001 B1
6299631 Shalaby Oct 2001 B1
6309569 Farrar et al. Oct 2001 B1
6312457 DiMatteo et al. Nov 2001 B1
6312474 Francis et al. Nov 2001 B1
6325810 Hamilton et al. Dec 2001 B1
6330965 Milliman et al. Dec 2001 B1
6398797 Bombard et al. Jun 2002 B2
6399362 Pui et al. Jun 2002 B1
6436030 Rehil Aug 2002 B2
6451029 Yeatman Sep 2002 B1
6454780 Wallace Sep 2002 B1
6461368 Fogarty et al. Oct 2002 B2
6488197 Whitman Dec 2002 B1
6491201 Whitman Dec 2002 B1
6494889 Fleischman et al. Dec 2002 B1
6500777 Wiseman et al. Dec 2002 B1
6503257 Grant et al. Jan 2003 B2
6514283 DiMatteo et al. Feb 2003 B2
6514534 Sawhney Feb 2003 B1
6517566 Hovland et al. Feb 2003 B1
6551356 Rousseau Apr 2003 B2
6565840 Clark et al. May 2003 B1
6566406 Pathak et al. May 2003 B1
6566407 Holmes-Farley et al. May 2003 B2
6568398 Cohen May 2003 B2
6589269 Zhu et al. Jul 2003 B2
6590095 Schleicher et al. Jul 2003 B1
6592597 Grant et al. Jul 2003 B2
6605294 Sawhney Aug 2003 B2
6610006 Amid et al. Aug 2003 B1
6620846 Jonn et al. Sep 2003 B1
6623452 Chien et al. Sep 2003 B2
6627749 Kumar Sep 2003 B1
6638285 Gabbay Oct 2003 B2
6652594 Francis et al. Nov 2003 B2
6656193 Grant et al. Dec 2003 B2
6656200 Li et al. Dec 2003 B2
6669735 Pelissier Dec 2003 B1
6673093 Sawhney Jan 2004 B1
6677258 Carroll et al. Jan 2004 B2
6681979 Whitman Jan 2004 B2
6685714 Rousseau Feb 2004 B2
6695199 Whitman Feb 2004 B2
6702731 Milbocker Mar 2004 B2
6702828 Whayne Mar 2004 B2
6703047 Sawhney et al. Mar 2004 B2
6704210 Myers Mar 2004 B1
6723114 Shalaby Apr 2004 B2
6726706 Dominguez Apr 2004 B2
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6746458 Cloud Jun 2004 B1
6746869 Pui et al. Jun 2004 B2
6764720 Pui et al. Jul 2004 B2
6773458 Brauker et al. Aug 2004 B1
6818018 Sawhney Nov 2004 B1
6835336 Watt Dec 2004 B2
6838493 Williams et al. Jan 2005 B2
6843252 Harrison et al. Jan 2005 B2
6846308 Whitman et al. Jan 2005 B2
6867247 Williams et al. Mar 2005 B2
6894140 Roby May 2005 B2
6896684 Monassevitch et al. May 2005 B2
6927315 Heinecke et al. Aug 2005 B1
6939358 Palacios et al. Sep 2005 B2
6946196 Foss Sep 2005 B2
6953139 Milliman et al. Oct 2005 B2
6959851 Heinrich Nov 2005 B2
7009034 Pathak et al. Mar 2006 B2
7025772 Gellman et al. Apr 2006 B2
7032798 Whitman et al. Apr 2006 B2
7060087 DiMatteo et al. Jun 2006 B2
7066934 Kirsch Jun 2006 B2
7087065 Ulmsten et al. Aug 2006 B2
7108701 Evens et al. Sep 2006 B2
7128253 Mastri et al. Oct 2006 B2
7128748 Mooradian et al. Oct 2006 B2
7129300 Roby Oct 2006 B2
7134438 Makower et al. Nov 2006 B2
7141055 Abrams et al. Nov 2006 B2
7147138 Shelton, IV Dec 2006 B2
7160299 Baily Jan 2007 B2
7179268 Roy et al. Feb 2007 B2
7210810 Iversen et al. May 2007 B1
7214727 Kwon et al. May 2007 B2
7217254 Kirwan et al. May 2007 B2
7232449 Sharkawy et al. Jun 2007 B2
7238195 Viola Jul 2007 B2
7241300 Sharkawy et al. Jul 2007 B2
7247338 Pui et al. Jul 2007 B2
7279322 Pui et al. Oct 2007 B2
7307031 Carroll et al. Dec 2007 B2
7308998 Mastri et al. Dec 2007 B2
7311720 Mueller et al. Dec 2007 B2
7328829 Arad et al. Feb 2008 B2
7334717 Rethy et al. Feb 2008 B2
7347850 Sawhney Mar 2008 B2
7377928 Zubik et al. May 2008 B2
7419081 Ehrenfels et al. Sep 2008 B2
7434717 Shelton, IV et al. Oct 2008 B2
7438209 Hess et al. Oct 2008 B1
7455682 Viola Nov 2008 B2
7464849 Shelton, IV et al. Dec 2008 B2
7498063 Pui et al. Mar 2009 B2
7547312 Bauman et al. Jun 2009 B2
7553923 Williams et al. Jun 2009 B2
7559937 de la Torre et al. Jul 2009 B2
7571845 Viola Aug 2009 B2
7588565 Marchitto et al. Sep 2009 B2
7592418 Pathak et al. Sep 2009 B2
7594921 Browning Sep 2009 B2
7595392 Kumar et al. Sep 2009 B2
7604151 Hess et al. Oct 2009 B2
7611494 Campbell et al. Nov 2009 B2
7635073 Heinrich Dec 2009 B2
7645874 Saferstein et al. Jan 2010 B2
7649089 Kumar et al. Jan 2010 B2
7655288 Bauman et al. Feb 2010 B2
7662409 Masters Feb 2010 B2
7662801 Kumar et al. Feb 2010 B2
7665646 Prommersberger Feb 2010 B2
7666198 Suyker et al. Feb 2010 B2
7669747 Weisenburgh, II et al. Mar 2010 B2
7673782 Hess et al. Mar 2010 B2
7699204 Viola Apr 2010 B2
7708180 Murray et al. May 2010 B2
7709631 Harris et al. May 2010 B2
7717313 Criscuolo et al. May 2010 B2
7722642 Williamson, IV et al. May 2010 B2
7735703 Morgan et al. Jun 2010 B2
7740160 Viola Jun 2010 B2
7744627 Orban, III Jun 2010 B2
7754002 Maase et al. Jul 2010 B2
7776060 Mooradian et al. Aug 2010 B2
7789889 Zubik et al. Sep 2010 B2
7793813 Bettuchi Sep 2010 B2
7799026 Schechter et al. Sep 2010 B2
7819896 Racenet Oct 2010 B2
7823592 Bettuchi et al. Nov 2010 B2
7824420 Eldridge et al. Nov 2010 B2
7845533 Marczyk et al. Dec 2010 B2
7845536 Viola et al. Dec 2010 B2
7846149 Jankowski Dec 2010 B2
7886951 Hessler Feb 2011 B2
7892247 Conston et al. Feb 2011 B2
7909224 Prommersberger Mar 2011 B2
7909837 Crews et al. Mar 2011 B2
7922743 Heinrich et al. Apr 2011 B2
7938307 Bettuchi May 2011 B2
7942890 D'Agostino et al. May 2011 B2
7950561 Aranyi May 2011 B2
7951166 Orban, III et al. May 2011 B2
7951248 Fallis et al. May 2011 B1
7967179 Olson et al. Jun 2011 B2
7988027 Olson et al. Aug 2011 B2
8011550 Aranyi et al. Sep 2011 B2
8011555 Tarinelli et al. Sep 2011 B2
8016177 Bettuchi et al. Sep 2011 B2
8016178 Olson et al. Sep 2011 B2
8025199 Whitman et al. Sep 2011 B2
8028883 Stopek Oct 2011 B2
8033483 Fortier et al. Oct 2011 B2
8033983 Chu et al. Oct 2011 B2
8038045 Bettuchi et al. Oct 2011 B2
8062330 Prommersberger et al. Nov 2011 B2
8062673 Figuly et al. Nov 2011 B2
8066169 Viola Nov 2011 B2
8083119 Prommersberger Dec 2011 B2
8091756 Viola Jan 2012 B2
8096458 Hessler Jan 2012 B2
8123766 Bauman et al. Feb 2012 B2
8123767 Bauman et al. Feb 2012 B2
8127975 Olson et al. Mar 2012 B2
8133336 Kettlewell et al. Mar 2012 B2
8133559 Lee et al. Mar 2012 B2
8146791 Bettuchi et al. Apr 2012 B2
8152777 Campbell et al. Apr 2012 B2
8157149 Olson et al. Apr 2012 B2
8157151 Ingmanson et al. Apr 2012 B2
8167895 D'Agostino et al. May 2012 B2
8177797 Shimoji et al. May 2012 B2
8178746 Hildeberg et al. May 2012 B2
8192460 Orban, III et al. Jun 2012 B2
8201720 Hessler Jun 2012 B2
8210414 Bettuchi et al. Jul 2012 B2
8210453 Hull et al. Jul 2012 B2
8215314 Chan et al. Jul 2012 B2
8225799 Bettuchi Jul 2012 B2
8225981 Criscuolo et al. Jul 2012 B2
8231043 Tarinelli et al. Jul 2012 B2
8235273 Olson et al. Aug 2012 B2
8245901 Stopek Aug 2012 B2
8252339 Figuly et al. Aug 2012 B2
8252921 Vignon et al. Aug 2012 B2
8256654 Bettuchi et al. Sep 2012 B2
8257391 Orban, III et al. Sep 2012 B2
8276800 Bettuchi Oct 2012 B2
8276802 Kostrzewski Oct 2012 B2
8281975 Criscuolo et al. Oct 2012 B2
8286849 Bettuchi Oct 2012 B2
8286850 Viola Oct 2012 B2
8308042 Aranyi Nov 2012 B2
8308045 Bettuchi et al. Nov 2012 B2
8308046 Prommersberger Nov 2012 B2
8312885 Bettuchi et al. Nov 2012 B2
8313014 Bettuchi Nov 2012 B2
8317790 Bell et al. Nov 2012 B2
8322588 Viola Dec 2012 B2
8322590 Patel et al. Dec 2012 B2
8348126 Olson et al. Jan 2013 B2
8348130 Shah et al. Jan 2013 B2
8353930 Heinrich et al. Jan 2013 B2
8365972 Aranyi et al. Feb 2013 B2
8367089 Wan et al. Feb 2013 B2
8371491 Huitema et al. Feb 2013 B2
8371492 Aranyi et al. Feb 2013 B2
8371493 Aranyi et al. Feb 2013 B2
8372094 Bettuchi et al. Feb 2013 B2
8393514 Shelton, IV et al. Mar 2013 B2
8393517 Milo Mar 2013 B2
8408440 Olson et al. Apr 2013 B2
8408480 Hull et al. Apr 2013 B2
8413869 Heinrich Apr 2013 B2
8413871 Racenet et al. Apr 2013 B2
8418909 Kostrzewski Apr 2013 B2
8424742 Bettuchi Apr 2013 B2
8430291 Heinrich et al. Apr 2013 B2
8453652 Stopek Jun 2013 B2
8453904 Eskaros et al. Jun 2013 B2
8453909 Olson et al. Jun 2013 B2
8453910 Bettuchi et al. Jun 2013 B2
8464925 Hull et al. Jun 2013 B2
8470360 McKay Jun 2013 B2
8474677 Woodard, Jr. et al. Jul 2013 B2
8479968 Hodgkinson et al. Jul 2013 B2
8485414 Criscuolo et al. Jul 2013 B2
8490853 Criscuolo et al. Jul 2013 B2
8496683 Prommersberger et al. Jul 2013 B2
8511533 Viola et al. Aug 2013 B2
8512402 Marczyk et al. Aug 2013 B2
8518440 Blaskovich et al. Aug 2013 B2
8529600 Woodard, Jr. et al. Sep 2013 B2
8540128 Shelton, IV et al. Sep 2013 B2
8540131 Swayze Sep 2013 B2
8551138 Orban, III et al. Oct 2013 B2
8556918 Bauman et al. Oct 2013 B2
8561873 Ingmanson et al. Oct 2013 B2
8579990 Priewe Nov 2013 B2
8584920 Hodgkinson Nov 2013 B2
8590762 Hess et al. Nov 2013 B2
8616429 Viola Dec 2013 B2
8616430 (Prommersberger) Stopek et al. Dec 2013 B2
8617132 Golzarian et al. Dec 2013 B2
8631989 Aranyi et al. Jan 2014 B2
8646674 Schulte et al. Feb 2014 B2
8668129 Olson Mar 2014 B2
8678263 Viola Mar 2014 B2
8679137 Bauman et al. Mar 2014 B2
8684250 Bettuchi Apr 2014 B2
8701958 Shelton, IV et al. Apr 2014 B2
8721703 Fowler May 2014 B2
8727197 Hess et al. May 2014 B2
8740844 Freyman et al. Jun 2014 B2
8757466 Olson et al. Jun 2014 B2
8789737 Hodgkinson et al. Jul 2014 B2
8814888 Sgro Aug 2014 B2
8820606 Hodgkinson Sep 2014 B2
8821523 Heinrich et al. Sep 2014 B2
8827133 Shelton, IV et al. Sep 2014 B2
8857694 Shelton, IV et al. Oct 2014 B2
8864009 Shelton, IV et al. Oct 2014 B2
8870050 Hodgkinson Oct 2014 B2
8875970 Viola Nov 2014 B2
8920443 Hiles et al. Dec 2014 B2
8920444 Hiles et al. Dec 2014 B2
8939344 Olson et al. Jan 2015 B2
8956390 Shah et al. Feb 2015 B2
8967448 Carter et al. Mar 2015 B2
9005243 Stopek et al. Apr 2015 B2
9010606 Aranyi et al. Apr 2015 B2
9010608 Casasanta, Jr. et al. Apr 2015 B2
9010609 Carter et al. Apr 2015 B2
9010610 Hodgkinson Apr 2015 B2
9010612 Stevenson et al. Apr 2015 B2
9016543 (Prommersberger) Stopek et al. Apr 2015 B2
9016544 Hodgkinson et al. Apr 2015 B2
9027817 Milliman et al. May 2015 B2
9044227 Shelton, IV et al. Jun 2015 B2
9055944 Hodgkinson et al. Jun 2015 B2
9084602 Gleiman Jul 2015 B2
9107665 Hodgkinson et al. Aug 2015 B2
9107667 Hodgkinson Aug 2015 B2
9113871 Milliman et al. Aug 2015 B2
9113872 Viola Aug 2015 B2
9113873 Marczyk et al. Aug 2015 B2
9113885 Hodgkinson et al. Aug 2015 B2
9113893 Sorrentino et al. Aug 2015 B2
9161753 Prior Oct 2015 B2
9161757 Bettuchi Oct 2015 B2
9186140 Hiles et al. Nov 2015 B2
9186144 Stevenson et al. Nov 2015 B2
9192378 Aranyi et al. Nov 2015 B2
9192379 Aranyi et al. Nov 2015 B2
9192380 (Tarinelli) Racenet et al. Nov 2015 B2
9192383 Milliman Nov 2015 B2
9192384 Bettuchi Nov 2015 B2
9198660 Hodgkinson Dec 2015 B2
9198663 Marczyk et al. Dec 2015 B1
9204881 Penna Dec 2015 B2
9220504 Viola et al. Dec 2015 B2
9226754 D'Agostino et al. Jan 2016 B2
9237892 Hodgkinson Jan 2016 B2
9237893 Carter et al. Jan 2016 B2
9277922 Carter et al. Mar 2016 B2
9295466 Hodgkinson et al. Mar 2016 B2
9326768 Shelton, IV May 2016 B2
9326773 Casasanta, Jr. et al. May 2016 B2
9328111 Zhou et al. May 2016 B2
9345479 (Tarinelli) Racenet et al. May 2016 B2
9351729 Orban, III et al. May 2016 B2
9351731 Carter et al. May 2016 B2
9351732 Hodgkinson May 2016 B2
9358005 Shelton, IV et al. Jun 2016 B2
9364229 D'Agostino et al. Jun 2016 B2
9364234 (Prommersberger) Stopek et al. Jun 2016 B2
9386988 Baxter, III et al. Jul 2016 B2
9402627 Stevenson et al. Aug 2016 B2
9414839 Penna Aug 2016 B2
9433412 Bettuchi et al. Sep 2016 B2
9433413 Stopek Sep 2016 B2
9433420 Hodgkinson Sep 2016 B2
9445812 Olson et al. Sep 2016 B2
9445817 Bettuchi Sep 2016 B2
9456821 Bettuchi et al. Oct 2016 B2
9463260 Stopek Oct 2016 B2
9486215 Olson et al. Nov 2016 B2
9492170 Bear et al. Nov 2016 B2
9504470 Milliman Nov 2016 B2
9517164 Vitaris et al. Dec 2016 B2
9572576 Hodgkinson et al. Feb 2017 B2
9585657 Shelton, IV et al. Mar 2017 B2
9597077 Hodgkinson Mar 2017 B2
9610080 Whitfield et al. Apr 2017 B2
9622745 Ingmanson et al. Apr 2017 B2
9629626 Soltz et al. Apr 2017 B2
9636850 Stopek (Prommersberger) et al. May 2017 B2
9655620 Prescott et al. May 2017 B2
9675351 Hodgkinson et al. Jun 2017 B2
9681936 Hodgkinson et al. Jun 2017 B2
9687262 Rousseau et al. Jun 2017 B2
9693772 Ingmanson et al. Jul 2017 B2
9708184 Chan et al. Jul 2017 B2
9770245 Swayze et al. Sep 2017 B2
9775617 Carter et al. Oct 2017 B2
9775618 Bettuchi et al. Oct 2017 B2
9782173 Mozdzierz Oct 2017 B2
9844378 Casasanta et al. Dec 2017 B2
9918713 Zergiebel et al. Mar 2018 B2
9931116 Racenet et al. Apr 2018 B2
10022125 (Prommersberger) Stopek et al. Jul 2018 B2
10076333 Bettuchi et al. Sep 2018 B2
10130368 Matonick Nov 2018 B2
10595873 Franklin, Sr. Mar 2020 B2
10743866 Scheib Aug 2020 B2
20010007069 Bombard et al. Jul 2001 A1
20020010482 Watt Jan 2002 A1
20020013591 Fleischman et al. Jan 2002 A1
20020026159 Zhu et al. Feb 2002 A1
20020028243 Masters Mar 2002 A1
20020049454 Whitman et al. Apr 2002 A1
20020091397 Chen Jul 2002 A1
20020151911 Gabbay Oct 2002 A1
20020156150 Williams et al. Oct 2002 A1
20020165559 Grant Nov 2002 A1
20020165562 Grant et al. Nov 2002 A1
20020173558 Williams et al. Nov 2002 A1
20030014064 Blatter Jan 2003 A1
20030032734 Roby Feb 2003 A1
20030050590 Kirsch Mar 2003 A1
20030065345 Weadock Apr 2003 A1
20030073981 Whitman et al. Apr 2003 A1
20030073982 Whitman Apr 2003 A1
20030078209 Schmidt Apr 2003 A1
20030083676 Wallace May 2003 A1
20030089757 Whitman May 2003 A1
20030111507 Nunez Jun 2003 A1
20030120284 Palacios et al. Jun 2003 A1
20030125676 Swenson et al. Jul 2003 A1
20030167064 Whayne Sep 2003 A1
20030181927 Wallace Sep 2003 A1
20030183671 Mooradian Oct 2003 A1
20030208231 Williamson et al. Nov 2003 A1
20030236518 Marchitto et al. Dec 2003 A1
20040002726 Nunez Jan 2004 A1
20040059283 Kirwan et al. Mar 2004 A1
20040068078 Milbocker Apr 2004 A1
20040092912 Jinno et al. May 2004 A1
20040092960 Abrams et al. May 2004 A1
20040093029 Zubik et al. May 2004 A1
20040107006 Francis et al. Jun 2004 A1
20040115229 Roby Jun 2004 A1
20040131418 Budde et al. Jul 2004 A1
20040236419 Milo Nov 2004 A1
20040254590 Hoffman et al. Dec 2004 A1
20040260315 Dell et al. Dec 2004 A1
20050002981 Lahtinen et al. Jan 2005 A1
20050006429 Wales et al. Jan 2005 A1
20050021085 Abrams et al. Jan 2005 A1
20050033331 Burnett et al. Feb 2005 A1
20050038471 Chan et al. Feb 2005 A1
20050043678 Freyman et al. Feb 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050059996 Bauman et al. Mar 2005 A1
20050059997 Bauman et al. Mar 2005 A1
20050070929 Dalessandro et al. Mar 2005 A1
20050096673 Stack et al. May 2005 A1
20050118435 DeLucia et al. Jun 2005 A1
20050143756 Jankowski Jun 2005 A1
20050149073 Arani et al. Jul 2005 A1
20050228446 Mooradian et al. Oct 2005 A1
20050230453 Viola Oct 2005 A1
20050267325 Bouchier Dec 2005 A1
20050283256 Sommerich et al. Dec 2005 A1
20060004407 Hiles et al. Jan 2006 A1
20060008505 Brandon Jan 2006 A1
20060085032 Viola Apr 2006 A1
20060085033 Criscuolo et al. Apr 2006 A1
20060108393 Heinrich et al. May 2006 A1
20060121266 Fandel et al. Jun 2006 A1
20060135992 Bettuchi et al. Jun 2006 A1
20060173470 Oray et al. Aug 2006 A1
20060178683 Shimoji et al. Aug 2006 A1
20060190027 Downey Aug 2006 A1
20060271104 Viola et al. Nov 2006 A1
20070026031 Bauman et al. Feb 2007 A1
20070034669 de la Torre et al. Feb 2007 A1
20070049953 Shimoji et al. Mar 2007 A2
20070123839 Rousseau et al. May 2007 A1
20070179528 Soltz et al. Aug 2007 A1
20070203509 Bettuchi Aug 2007 A1
20070203510 Bettuchi Aug 2007 A1
20070243227 Gertner Oct 2007 A1
20070246505 Pace-Floridia et al. Oct 2007 A1
20080009811 Cantor Jan 2008 A1
20080029570 Shelton et al. Feb 2008 A1
20080082126 Murray et al. Apr 2008 A1
20080110959 Orban et al. May 2008 A1
20080125812 Zubik et al. May 2008 A1
20080140115 Stopek Jun 2008 A1
20080161831 Bauman et al. Jul 2008 A1
20080161832 Bauman et al. Jul 2008 A1
20080169327 Shelton et al. Jul 2008 A1
20080169328 Shelton Jul 2008 A1
20080169329 Shelton et al. Jul 2008 A1
20080169330 Shelton et al. Jul 2008 A1
20080169331 Shelton et al. Jul 2008 A1
20080169332 Shelton et al. Jul 2008 A1
20080169333 Shelton et al. Jul 2008 A1
20080200949 Hiles et al. Aug 2008 A1
20080216855 Nasca Sep 2008 A1
20080220047 Sawhney et al. Sep 2008 A1
20080230583 Heinrich Sep 2008 A1
20080290134 Bettuchi et al. Nov 2008 A1
20080308608 Prommersberger Dec 2008 A1
20080314960 Marczyk et al. Dec 2008 A1
20090001121 Hess et al. Jan 2009 A1
20090001122 Prommersberger et al. Jan 2009 A1
20090001123 Morgan et al. Jan 2009 A1
20090001124 Hess et al. Jan 2009 A1
20090001125 Hess et al. Jan 2009 A1
20090001126 Hess et al. Jan 2009 A1
20090001128 Weisenburgh, II et al. Jan 2009 A1
20090001130 Hess et al. Jan 2009 A1
20090005808 Hess et al. Jan 2009 A1
20090030452 Bauman et al. Jan 2009 A1
20090031842 Kawai et al. Feb 2009 A1
20090043334 Bauman et al. Feb 2009 A1
20090076510 Bell et al. Mar 2009 A1
20090076528 Sgro Mar 2009 A1
20090078739 Viola Mar 2009 A1
20090095791 Eskaros et al. Apr 2009 A1
20090095792 Bettuchi Apr 2009 A1
20090120994 Murray et al. May 2009 A1
20090134200 Tarinelli et al. May 2009 A1
20090206125 Huitema et al. Aug 2009 A1
20090206126 Huitema et al. Aug 2009 A1
20090206139 Hall et al. Aug 2009 A1
20090206141 Huitema et al. Aug 2009 A1
20090206142 Huitema et al. Aug 2009 A1
20090206143 Huitema et al. Aug 2009 A1
20090218384 Aranyi Sep 2009 A1
20090277944 Dalessandro et al. Nov 2009 A9
20090277947 Viola Nov 2009 A1
20090287230 D'Agostino et al. Nov 2009 A1
20100012704 Tarinelli Racenet et al. Jan 2010 A1
20100016855 Ramstein et al. Jan 2010 A1
20100016888 Calabrese et al. Jan 2010 A1
20100065606 Stopek Mar 2010 A1
20100065607 Orban, III et al. Mar 2010 A1
20100072254 Aranyi et al. Mar 2010 A1
20100087840 Ebersole et al. Apr 2010 A1
20100147921 Olson Jun 2010 A1
20100147922 Olson Jun 2010 A1
20100147923 D'Agostino et al. Jun 2010 A1
20100174253 Cline et al. Jul 2010 A1
20100203151 Hiraoka Aug 2010 A1
20100230466 Criscuolo et al. Sep 2010 A1
20100243707 Olson et al. Sep 2010 A1
20100243708 Aranyi et al. Sep 2010 A1
20100243711 Olson et al. Sep 2010 A1
20100249805 Olson et al. Sep 2010 A1
20100264195 Bettuchi Oct 2010 A1
20100282815 Bettuchi et al. Nov 2010 A1
20100331859 Omori Dec 2010 A1
20100331880 Stopek Dec 2010 A1
20110024476 Bettuchi et al. Feb 2011 A1
20110024481 Bettuchi et al. Feb 2011 A1
20110034910 Ross et al. Feb 2011 A1
20110036889 Heinrich et al. Feb 2011 A1
20110036894 Bettuchi Feb 2011 A1
20110042442 Viola et al. Feb 2011 A1
20110046650 Bettuchi Feb 2011 A1
20110057016 Bettuchi Mar 2011 A1
20110087279 Shah et al. Apr 2011 A1
20110089220 Ingmanson et al. Apr 2011 A1
20110125138 Malinouskas et al. May 2011 A1
20110166673 Patel et al. Jul 2011 A1
20110215132 Aranyi et al. Sep 2011 A1
20110278346 Hull Nov 2011 A1
20110293690 Griffin et al. Dec 2011 A1
20120074199 Olson et al. Mar 2012 A1
20120080336 Shelton, IV et al. Apr 2012 A1
20120083723 Vitaris et al. Apr 2012 A1
20120187179 Gleiman Jul 2012 A1
20120197272 Oray et al. Aug 2012 A1
20120241491 Aldridge et al. Sep 2012 A1
20120241493 Baxter, III et al. Sep 2012 A1
20120241499 Baxter, III et al. Sep 2012 A1
20120253298 Henderson et al. Oct 2012 A1
20120273547 Hodgkinson et al. Nov 2012 A1
20130008937 Viola Jan 2013 A1
20130037596 Bear et al. Feb 2013 A1
20130105548 Hodgkinson et al. May 2013 A1
20130105553 (Tarinelli) Racenet et al. May 2013 A1
20130112732 Aranyi et al. May 2013 A1
20130112733 Aranyi et al. May 2013 A1
20130146641 Shelton, IV et al. Jun 2013 A1
20130153633 Casasanta, Jr. et al. Jun 2013 A1
20130153634 Carter et al. Jun 2013 A1
20130153635 Hodgkinson Jun 2013 A1
20130153636 Shelton, IV et al. Jun 2013 A1
20130153638 Carter et al. Jun 2013 A1
20130153639 Hodgkinson et al. Jun 2013 A1
20130153640 Hodgkinson Jun 2013 A1
20130153641 Shelton, IV et al. Jun 2013 A1
20130161374 Swayze et al. Jun 2013 A1
20130181031 Olson et al. Jul 2013 A1
20130193186 (Tarinelli) Racenet et al. Aug 2013 A1
20130193190 Carter et al. Aug 2013 A1
20130193191 Stevenson et al. Aug 2013 A1
20130193192 Casasanta, Jr. et al. Aug 2013 A1
20130209659 Racenet et al. Aug 2013 A1
20130221062 Hodgkinson Aug 2013 A1
20130240600 Bettuchi Sep 2013 A1
20130240601 Bettuchi et al. Sep 2013 A1
20130240602 Stopek Sep 2013 A1
20130256380 Schmid et al. Oct 2013 A1
20130277411 Hodgkinson et al. Oct 2013 A1
20130292449 Bettuchi et al. Nov 2013 A1
20130306707 Viola et al. Nov 2013 A1
20130310873 Stopek (Prommersberger) et al. Nov 2013 A1
20130327807 Olson et al. Dec 2013 A1
20140012317 Orban et al. Jan 2014 A1
20140021242 Hodgkinson et al. Jan 2014 A1
20140027490 Marczyk et al. Jan 2014 A1
20140034704 Ingmanson et al. Feb 2014 A1
20140048580 Merchant et al. Feb 2014 A1
20140061280 Ingmanson et al. Mar 2014 A1
20140061281 Hodgkinson Mar 2014 A1
20140084042 (Prommersberger) Stopek et al. Mar 2014 A1
20140097224 Prior Apr 2014 A1
20140117066 Aranyi et al. May 2014 A1
20140130330 Olson et al. May 2014 A1
20140131418 Kostrzewski May 2014 A1
20140131419 Bettuchi May 2014 A1
20140138423 Whitfield et al. May 2014 A1
20140151431 Hodgkinson et al. Jun 2014 A1
20140155916 Hodgkinson et al. Jun 2014 A1
20140158742 Stopek (Prommersberger) et al. Jun 2014 A1
20140166721 Stevenson et al. Jun 2014 A1
20140197224 Penna Jul 2014 A1
20140203061 Hodgkinson Jul 2014 A1
20140217147 Milliman Aug 2014 A1
20140217148 Penna Aug 2014 A1
20140231488 Holsten Aug 2014 A1
20140239046 Milliman Aug 2014 A1
20140239047 Hodgkinson et al. Aug 2014 A1
20140252062 Mozdzierz Sep 2014 A1
20150001276 Hodgkinson et al. Jan 2015 A1
20150041347 Hodgkinson Feb 2015 A1
20150097018 Hodgkinson Apr 2015 A1
20150115015 Prescott et al. Apr 2015 A1
20150133995 Shelton, IV et al. May 2015 A1
20150157321 Zergiebel et al. Jun 2015 A1
20150209045 Hodgkinson et al. Jul 2015 A1
20150231409 Racenet et al. Aug 2015 A1
20150327864 Hodgkinson et al. Nov 2015 A1
20150351753 Shelton, IV et al. Dec 2015 A1
20150351758 Shelton, IV et al. Dec 2015 A1
20160022268 Prior Jan 2016 A1
20160045200 Milliman Feb 2016 A1
20160095592 Levinson et al. Apr 2016 A1
20160100834 Viola et al. Apr 2016 A1
20160106430 Carter et al. Apr 2016 A1
20160157857 Hodgkinson et al. Jun 2016 A1
20160174988 D'Agostino et al. Jun 2016 A1
20160206315 Olson Jul 2016 A1
20160220257 Casasanta et al. Aug 2016 A1
20160249923 Hodgkinson et al. Sep 2016 A1
20160270793 Carter et al. Sep 2016 A1
20160310143 Bettuchi Oct 2016 A1
20160338704 Penna Nov 2016 A1
20160367252 Olson et al. Dec 2016 A1
20160367253 Hodgkinson Dec 2016 A1
20160367257 Stevenson et al. Dec 2016 A1
20170042540 Olson et al. Feb 2017 A1
20170049452 Milliman Feb 2017 A1
20170150967 Hodgkinson et al. Jun 2017 A1
20170172575 Hodgkinson Jun 2017 A1
20170231629 Stopek et al. Aug 2017 A1
20170238931 Prescott et al. Aug 2017 A1
20170281328 Hodgkinson et al. Oct 2017 A1
20170296188 Ingmanson et al. Oct 2017 A1
20170354415 Casasanta, Jr. et al. Dec 2017 A1
20180085120 Viola Mar 2018 A1
20180125491 Aranyi May 2018 A1
20180140301 Milliman May 2018 A1
20180168654 Hodgkinson et al. Jun 2018 A1
20180214147 Merchant et al. Aug 2018 A1
Foreign Referenced Citations (85)
Number Date Country
2282761 Sep 1998 CA
2 667 434 May 2008 CA
101310680 Nov 2008 CN
101332110 Dec 2008 CN
1602563 Mar 1950 DE
19924311 Nov 2000 DE
0327022 Aug 1989 EP
0577373 Jan 1994 EP
0594148 Apr 1994 EP
0667119 Aug 1995 EP
1064883 Jan 2001 EP
1256317 Nov 2002 EP
1256318 Nov 2002 EP
1520525 Apr 2005 EP
1621141 Feb 2006 EP
1702570 Sep 2006 EP
1759640 Mar 2007 EP
1815804 Aug 2007 EP
1825820 Aug 2007 EP
1929958 Jun 2008 EP
1994890 Nov 2008 EP
2005894 Dec 2008 EP
2005895 Dec 2008 EP
2008595 Dec 2008 EP
2039308 Mar 2009 EP
2090231 Aug 2009 EP
2090244 Aug 2009 EP
2090252 Aug 2009 EP
2163211 Mar 2010 EP
2189121 May 2010 EP
2198787 Jun 2010 EP
2236098 Oct 2010 EP
2236099 Oct 2010 EP
2258282 Dec 2010 EP
2292276 Mar 2011 EP
2311386 Apr 2011 EP
2436348 Apr 2012 EP
2462880 Jun 2012 EP
2491867 Aug 2012 EP
2497431 Sep 2012 EP
2517637 Oct 2012 EP
2586380 May 2013 EP
2604195 Jun 2013 EP
2604197 Jun 2013 EP
2620105 Jul 2013 EP
2620106 Jul 2013 EP
2630922 Aug 2013 EP
2644125 Oct 2013 EP
2762091 Aug 2014 EP
06327683 Nov 1994 JP
2000166933 Jun 2000 JP
2002202213 Jul 2002 JP
2007124166 May 2007 JP
2010214132 Sep 2010 JP
9005489 May 1990 WO
9516221 Jun 1995 WO
9622055 Jul 1996 WO
9801989 Jan 1997 WO
9713463 Apr 1997 WO
9817180 Apr 1998 WO
9838923 Sep 1998 WO
9926826 Jun 1999 WO
9945849 Sep 1999 WO
0010456 Mar 2000 WO
0016684 Mar 2000 WO
0056376 Sep 2000 WO
0162158 Aug 2001 WO
0162162 Aug 2001 WO
2002030297 Apr 2002 WO
0308844 Oct 2003 WO
03082126 Oct 2003 WO
03088845 Oct 2003 WO
03094743 Nov 2003 WO
03094746 Nov 2003 WO
03105698 Dec 2003 WO
2005079675 Sep 2005 WO
2006023578 Mar 2006 WO
2006044490 Apr 2006 WO
2006083748 Aug 2006 WO
2007121579 Nov 2007 WO
2008057281 May 2008 WO
2008109125 Sep 2008 WO
2010075298 Jul 2010 WO
2011143183 Nov 2011 WO
2012044848 Apr 2012 WO
Non-Patent Literature Citations (76)
Entry
International Search Report corresponding to European Application No. EP 05809831.0-1269, completed on May 4, 2012 and dated May 14, 2012; 10 pages.
Extended European Search Report corresponding to EP 14 16 9739.1, completed Aug. 9, 2014 and dated Aug. 29, 2014; (7 pp).
Extended European Search Report corresponding to EP 14 15 7997.9, completed Sep. 9, 2014 and dated Sep. 17, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 16 8904.2, completed Sep. 10, 2014 and dated Sep. 18, 2014; (8 pp).
Extended European Search Report corresponding to EP 13 19 4995.0, completed Jun. 5, 2014 and dated Oct. 13, 2014; (10 pp).
Extended European Search Report corresponding to EP 13 15 4571.7, completed Oct. 10, 2014 and dated Oct. 20, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 18 1125.7, completed Oct. 16, 2014 and dated Oct. 24, 2014; (7 pp).
Extended European Search Report corresponding to EP 14 18 1127.3, completed Oct. 16, 2014 and dated Nov. 10, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 19 0419.3, completed Mar. 24, 2015 and dated Mar. 30, 2015; (6 pp).
European Search Report corresponding to EP 05 02 2585.3, completed Jan. 25, 2006 and dated Feb. 3, 2006; 4 pages.
European Search Report corresponding to EP 06 00 4598, completed Jun. 22, 2006; 2 pages.
European Search Report corresponding to EP 06 01 6962.0, completed Jan. 3, 2007 and dated Jan. 11, 2007; 10 pages.
International Search Report corresponding to International Application No. PCT/US2005/036740, completed Feb. 20, 2007 and dated Mar. 23, 2007; 8 pages.
International Search Report corresponding to International Application No. PCT/US2007/022713, completed Apr. 21, 2008 and dated May 15, 2008; 1 page.
International Search Report corresponding to International Application No. PCT/US2008/002981, completed Jun. 9, 2008 and dated Jun. 26, 2008; 2 pages.
European Search Report corresponding to EP 08 25 1779, completed Jul. 14, 2008 and dated Jul. 23, 2008; 5 pages.
European Search Report corresponding to EP 08 25 1989.3, completed Mar. 11, 2010 and dated Mar. 24, 2010; 6 pages.
European Search Report corresponding to EP 10 25 0639.1, completed Jun. 17, 2010 and dated Jun. 28, 2010; 7 pages.
European Search Report corresponding to EP 10 25 0715.9, completed Jun. 30, 2010 and dated Jul. 20, 2010; 3 pages.
European Search Report corresponding to EP 05 80 4382.9, completed Oct. 5, 2010 and dated Oct. 12, 2010; 3 pages.
European Search Report corresponding to EP 10 25 1437.9, completed Nov. 22, 2010 and dated Dec. 16, 2010; 3 pages.
European Search Report corresponding to EP 09 25 2897.5, completed Feb. 7, 2011 and dated Feb. 15, 2011; 3 pages.
European Search Report corresponding to EP 10 25 0642.5, completed Mar. 25, 2011 and dated Apr. 4, 2011; 4 pages.
European Search Report corresponding to EP 11 18 8309.6, completed Dec. 15, 2011 and dated Jan. 12, 2012; 3 pages.
European Search Report corresponding to EP 12 15 2229.6, completed Feb. 23, 2012 and dated Mar. 1, 2012; 4 pages.
European Search Report corresponding to EP 12 15 0511.9, completed Apr. 16, 2012 and dated Apr. 24, 2012; 7 pages.
European Search Report corresponding to EP 12 15 2541.4, completed Apr. 23, 2012 and dated May 3, 2012; 10 pages.
European Search Report corresponding to EP 12 16 5609.4, completed Jul. 5, 2012 and dated Jul. 13, 2012; 8 pages.
European Search Report corresponding to EP 12 15 8861.0, completed Jul. 17, 2012 and dated Jul. 24, 2012; 9 pages.
European Search Report corresponding to EP 12 16 5878.5, completed Jul. 24, 2012 and dated Aug. 6, 2012; 8 pages.
Extended European Search Report corresponding to EP 12 19 1035.0, completed Jan. 11, 2013 and dated Jan. 18, 2013; 7 pages.
Extended European Search Report corresponding to EP 12 18 6175.1, completed Jan. 15, 2013 and dated Jan. 23, 2013; 7 pages.
Extended European Search Report corresponding to EP 12 19 1114.3, completed Jan. 23, 2013 and dated Jan. 31, 2013; 10 pages.
Extended European Search Report corresponding to EP 12 19 2224.9, completed Mar. 14, 2013 and dated Mar. 26, 2013; 8 pages.
Extended European Search Report corresponding to EP 12 19 6911.7, completed Apr. 18, 2013 and dated Apr. 24, 2013; 8 pages.
Extended European Search Report corresponding to EP 08 72 6500.5, completed Feb. 20, 2014 and dated Mar. 3, 2014; (7 pp).
Extended European Search Report corresponding to EP 13 19 5919.9, completed Feb. 10, 2014 and dated Mar. 3, 2014; (7 pp).
Extended European Search Report corresponding to EP 13 19 2123.1, completed Jan. 30, 2014 and dated Feb. 10, 2014; (8 pp).
Extended European Search Report corresponding to EP 13 19 6816.6, completed Mar. 28, 2014 and dated Apr. 9, 2014; (9 pp).
Extended European Search Report corresponding to EP 13 19 4995.0, completed Jun. 5, 2014 and dated Jun. 16, 2014; (5 pp).
Extended European Search Report corresponding to EP 13 19 5019.8, completed Mar. 14, 2014 and dated Mar. 24, 2014; (7 pp).
Extended European Search Report corresponding to EP 13 19 2111.6, completed Feb. 13, 2014 and dated Feb. 27, 2014; (10 pp).
Extended European Search Report corresponding to EP 13 19 7958.5, completed Apr. 4, 2014 and dated Apr. 15, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 15 6342.9, completed Jul. 22, 2014 and dated Jul. 29, 2014; (8 pp).
Extended European Search Report corresponding to EP 14 15 7195.0, completed Jun. 5, 2014 and dated Jun. 18, 2014; (9 pp).
Extended European Search Report corresponding to EP 12 19 6904.2, completed Mar. 28, 2013 and dated Jul. 26, 2013; 8 pages.
Extended European Search Report corresponding to EP 12 19 8749.9, completed May 21, 2013 and dated May 31, 2013; 8 pages.
Extended European Search Report corresponding to EP 07 00 5842.5, completed May 13, 2013 and dated May 29, 2013; 7 pages.
Extended European Search Report corresponding to EP 12 19 8776.2, completed May 16, 2013 and dated May 27, 2013; 8 pages.
Extended European Search Report corresponding to EP 13 15 6297.7, completed Jun. 4, 2013 and dated Jun. 13, 2013; 7 pages.
Extended European Search Report corresponding to EP 13 17 3985.6, completed Aug. 19, 2013 and dated Aug. 28, 2013; 6 pages.
Extended European Search Report corresponding to EP 13 17 3986.4, completed Aug. 20, 2013 and dated Aug. 29, 2013; 7 pages.
Extended European Search Report corresponding to EP 13 17 7437.4, completed Sep. 11, 2013 and dated Sep. 19, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 7441.6, completed Sep. 11, 2013 and dated Sep. 19, 2013; (6 pp).
Extended European Search Report corresponding to EP 07 86 1534.1, completed Sep. 20, 2013 and dated Sep. 30, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 18 3876.5, completed Oct. 14, 2013 and dated Oct. 24, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 17 1856.1, completed Oct. 29, 2013 and dated Nov. 7, 2013; (8 pp).
Extended European Search Report corresponding to EP 13 18 0373.6, completed Oct. 31, 2013 and dated Nov. 13, 2013; (7 pp).
Extended European Search Report corresponding to EP 13 18 0881.8, completed Nov. 5, 2013 and dated Nov. 14, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 6895.4, completed Nov. 29, 2013 and dated Dec. 12, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 18 2911.1, completed Dec. 2, 2013 and dated Dec. 16, 2013; (8 pp).
Extended European Search Report corresponding to EP 10 25 1795.0, completed Dec. 11, 2013 and dated Dec. 20, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 18 7911.6, completed Jan. 22, 2014 and dated Jan. 31, 2014; (8 pp).
European Office Action corresponding to counterpart Int'l Appln No. EP 12 198 776.2 dated Apr. 7, 2015.
European Office Action corresponding to counterpart Int'l Appln No. EP 13 156 297.7 dated Apr. 10, 2015.
Australian Examination Report No. 1 corresponding to counterpart Int'l Appln No. AU 2011250822 dated May 18, 2015.
European Office Action corresponding to counterpart Int'l Appln No. EP 12 186 175.1 dated Jun. 1, 2015.
Chinese Office Action corresponding to counterpart Int'l Appln No. CN 201010517292.8 dated Jun. 2, 2015.
Extended European Search Report corresponding to counterpart Int'l Appln No. EP 14 17 48145 dated Jun. 9, 2015.
Australian Examination Report No. 1 corresponding to counterpart Int'l Appln No. AU 2014200584 dated Jun. 15, 2015.
European Office Action corresponding to counterpart Int'l Appln No. EP 13 180 881.8 dated Jun. 19, 2015.
European Office Action corresponding to counterpart Int'l Appln No. EP 14 157 195.0 dated Jul. 2, 2015.
Extended European Search Report corresponding to counterpart Int'l Appln No. EP 12 19 6902.6 dated Aug. 6, 2015.
Extended European Search Report corresponding to counterpart Int'l Appln No. EP 14 15 2060.1 dated Aug. 14, 2015.
Chinese Office Action corresponding to counterpart Int'l Appln No. CN 201210129787.2 dated Aug. 24, 2015.
International Search Report corresponding to European Application No. EP 05809831.0-1269, dated May 14, 2012.
Related Publications (1)
Number Date Country
20190175180 A1 Jun 2019 US
Provisional Applications (2)
Number Date Country
60620065 Oct 2004 US
60620066 Oct 2004 US
Divisions (2)
Number Date Country
Parent 13848265 Mar 2013 US
Child 15201875 US
Parent 11241267 Sep 2005 US
Child 13076550 US
Continuations (2)
Number Date Country
Parent 15201875 Jul 2016 US
Child 16278801 US
Parent 13076550 Mar 2011 US
Child 13848265 US